Track market-moving stories before they get noisy

Sony Today

$20.88 -0.28 (-1.30%)

As of 09:57 AM Eastern

This is a fair market value price provided by Massive. Learn more.

52-Week Range$19.32▼

$30.34Dividend Yield0.53%

Price Target$22.00

Sony Corp. NYSE: SONY announced plans to discontinue its physical gaming discs starting in 2028. According to the company, the move is being made to coincide with consumer preferences. That sentiment is backed up by Take-Two Interactive NASDAQ: TTWO , which announced that its latest version of Grand Theft Auto will be available exclusively in a digital format.

SONY hasn’t moved much since the announcement, and for good reason. The issue of physical discs doesn’t address the larger threat that’s facing the gaming industry as a whole. 

Get Sony alerts:

For updates on that front, investors will have to wait for the company’s earnings report, which is due in early August.

Memory Costs Remain Sony's Biggest Gaming HeadwindThe short-term reaction to the phase-out news was predictable. The decision will lead to cost savings, which investors love. It also has the potential to improve margins.

But it does nothing to address the memory issue, which will still be front and center for Sony and other gaming companies, such as Microsoft NASDAQ: MSFT. Microsoft has recently announced company-wide layoffs of up to 4,800 workers. However, most of those displaced will come from its gaming division, which is struggling with higher memory costs for its Xbox.

Sony faces those issues with its PlayStation console, but on a much greater scale. Sony's PlayStation 5 currently dominates in market share with an estimated 75 million active units globally. That’s a stark contrast to the 30 million units sold across the Xbox Series ecosystem.

That means the company faces a memory issue that’s literally twice as large as that of Microsoft and even more so than that of Take-Two.

Sony's Move Away From Discs Raises Ownership ConcernsSony’s decision, on top of Take-Two's move, is a shot across the bow at a company like GameStop NYSE: GME, which still generates a significant share of its revenue from physical gaming hardware, including discs. But that’s been a known issue for years. GameStop has closed over 1,300 stores in the last two fiscal years due to dwindling demand for physical games.

The real backlash is coming from collectors and physical media loyalists who have now lost the ability to resell, lend, or buy used games. Eliminating discs ties ownership more tightly to platform accounts/servers. The argument is that the absence of physical discs eliminates the second-hand market and gives consumers no alternative to the PlayStation Store. That means after 2028, Sony will be the only arbiter over what a game costs and how long users can use it.

On one level, the concerns hold some merit. If Sony decides to delist a title, gamers who don’t own the physical disc could lose access entirely. Even if they have a physical disc, the functionality will be limited to that version.

Those concerns are coming to a head in a lawsuit by a Dutch law firm, which is seeking $457 billion dollars in damages. The “Fair PlayStation” campaign addresses the “Sony tax,” which refers to the 30% commission that Sony levies on all products sold through its stores.

Plus, the announcement comes shortly after Sony raised the price of its disc-edition PlayStation to $649.99 from $549.99—a not-so-subtle way to nudge consumers to higher-margin digital sales. It may be a coincidence, but the optics give the critics some validity.

However, the real erosion of consumer ownership rights is mostly an argument dressed in nostalgia's clothing. No privacy rights are being lost, and Sony’s larger point is correct. More gamers are simply choosing to download the updated version of a game.

SONY Stock Analysis: Technical Signals Point to Limited UpsideSONY is down about 17% in 2026. The good news is that it looks like it’s formed a bottom at just under $20 per share. The concern is that the upside may be limited without better momentum.

The Sony analyst forecasts on MarketBeat show a consensus price target of $22, which leaves less than 4% by way of upside. Assuming earnings growth of around 10% in the next 12 months, the company’s annual dividend looks safe and may increase. But the yield of 0.5% may not be enough to keep investors interested.

The daily chart supports a case for cautious optimism, but with a big asterisk. Shares have climbed off their recent low to about $21, and the MACD line has crossed above its signal line, a bullish signal that often precedes further near-term gains. That said, the stock remains well below its 200-day simple moving average of $24.05, a level SONY hasn't reclaimed since December 2025.

That gap between improving short-term momentum and a still-declining long-term trend line is exactly why the upside looks capped. A bounce off support isn't the same as a confirmed reversal, and bulls likely need a close above the 200-day average before the broader downtrend is truly broken.

Should You Invest $1,000 in Sony Right Now?Before you consider Sony, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sony wasn't on the list.

While Sony currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 9.55% in early trading, wiping £19 billion from the company's valuation, after its Wainua drug failed a closely watched Phase III trial in a form of heart disease.

The drop propelled the stock to the top of the FTSE 100 losers' list.

The CARDIO-TTRansform trial, run with US partner Ionis, tested Wainua in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a progressive and often fatal condition in which misfolded protein builds up in the heart.

The study did not meet its primary endpoint of reducing cardiovascular deaths and recurrent cardiovascular events over 140 weeks compared with placebo.

AstraZeneca said adding Wainua to today's standard of care, which included a stabiliser treatment for most patients, provided no statistically significant benefit.

In a prespecified subgroup of patients receiving Wainua on its own, fewer events were observed and the result was nominally significant, though no treatment effect was seen in patients already on stabiliser therapy.

The trial was the largest ever run in ATTR-CM, enrolling 1,432 patients across 130 sites in 20 countries.

Full data will be presented at the European Society of Cardiology Congress in August.

Sharon Barr, head of biopharmaceuticals research and development at AstraZeneca, said that although the trial missed its primary objective, the results support greater scientific understanding of treatment approaches for the hundreds of thousands of patients living with the disease worldwide.

The readout was one of three major Phase III catalysts hanging over the stock in the second half, alongside the SERENA-4 trial of breast cancer drug camizestrant and the AVANZAR lung cancer study of Datroway.

Citi, which has a buy rating on the shares, had modelled peak Wainua sales in ATTR-CM of around $6.2 billion, with a 59% probability of success, making it the highest-conviction of the three readouts.

The bank estimated in May that a failure of CARDIO-TTRansform would knock around 2.8% off its discounted cash flow valuation, equivalent to roughly £5.20 off its £181 fair value estimate.

Notably, Citi argued at the time that the roughly 10% fall in AstraZeneca shares from their pre-results highs already exceeded the combined 7% downside it attributed to the failure of all three trials.

Even in a scenario where all three readouts disappointed, the bank calculated a bear-case valuation of £168, still 23% above where the shares were then trading.

The broker's bull case, assuming success across all three, pointed to a valuation of around £204.

Today's sell-off suggests the market is pricing in a harsher read-across, with investors likely reassessing the risk attached to the remaining SERENA-4 and AVANZAR readouts later this year.

Citi has consistently described AstraZeneca as having the best growth and best pipeline in European pharma, with $46 billion of risk-adjusted peak pipeline sales and ten Phase III readouts due in 2026.

Wainua is already approved in more than 20 countries for the polyneuropathy of hereditary transthyretin-mediated amyloidosis, a separate nerve-damage indication unaffected by today's result.

Micron raises its planned U.S. investment to more than $250 billion through 2035 and celebrates a construction milestone at what will be the largest semiconductor manufacturing site in U.S. history July 09, 2026 08:45 ET  | Source: Micron Technology, Inc.

CLAY, N.Y., July 09, 2026 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq: MU) today announced it is accelerating its planned U.S. fab and technology investments and increasing its expected spend to more than $250 billion through 2035, driven by surging demand for memory in the AI era.

Micron anticipates that the increase in investments will support its long-term goal of producing 40% of its DRAM in the U.S. while creating additional good-paying direct and indirect jobs. The expanded investment reflects Micron’s confidence in its technology leadership and continued demand for its leading-edge memory products.

The announcement comes as Micron celebrates the first concrete pour milestone at its Clay, New York site, which occurs more than one quarter ahead of the original plan and marks the transition from site preparation to vertical construction. As announced earlier today, Micron also plans to invest up to $3 billion to develop the domestic semiconductor supply chain ecosystem in support of its U.S. manufacturing footprint.

Today, Micron Chairman, President and CEO Sanjay Mehrotra will host the concrete pour, joined by supplier partners and federal, state and local leaders, including U.S. Secretary of Commerce Howard Lutnick, New York Governor Kathy Hochul, Small Business Administration Administrator Kelly Loeffler, U.S. Chief Technology Officer Dr. Ethan Klein, Onondaga County Executive Ryan McMahon, U.S. Congressman John Mannion, U.S. Congresswoman Claudia Tenney, and Town of Clay Deputy Supervisor Joe Bick.

"As America celebrates its 250th anniversary, data and memory are foundational to the modern economy — and Micron is increasing our U.S. investments to more than $250 billion through 2035 to meet that moment," said Sanjay Mehrotra, Micron Chairman, President, and CEO. "I want to thank President Trump, Secretary Lutnick, Governor Hochul, Senator Schumer, County Executive McMahon, and our partners across government and the community for their leadership. Reaching this milestone ahead of schedule reflects the speed and determination behind this project. Micron is proud to bring the world's most advanced memory manufacturing to Central New York, strengthen the domestic semiconductor supply chain and help secure America's technology leadership for generations to come."

A Media Snippet accompanying this announcement is available by clicking on this link.

“President Trump has made it clear that America is where you should build your business and the world is responding rapidly. Today, Micron pours the foundation on its massive semiconductor campus in upstate New York and increases its American investment commitment to $250 billion, creating nearly 100,000 jobs and providing leading-edge memory supply here in the United States,” said Commerce Secretary Howard Lutnick. “The Trump economic model clearly shows there has never been a better time to invest in the United States.”

"Today's milestone marks another major step for Micron in Central New York, and what makes it even more remarkable is that we're here in July — months ahead of schedule — pouring the concrete foundation,” said Governor Kathy Hochul. “This is the largest private investment in New York State history, and it's already delivering for New Yorkers, our state economy, and our local businesses. With up to 50,000 jobs on the horizon, we are building the future of American memory manufacturing right here in Central New York, and we are building it fast."

Rapid progress in Central New York

Less than six months after breaking ground in January 2026, Micron has completed key early site work and is transitioning to vertical construction. Micron recently selected Bechtel to partner on the engineering, procurement and construction for the first New York fab. Jacobs, the architectural and engineering design partner, and Gilbane Building Company, the preconstruction and site infrastructure contractor, will also join the celebration.

To date, Micron, in partnership with Gilbane on the early site works phase, has directed approximately $675 million — more than half of the total awarded value to date — to New York-based contractors, suppliers, and subcontractors, including companies from Syracuse, Liverpool, Rome, Rochester, Watertown, Buffalo, and Binghamton. More than 80% of the workers on site to date have been New York residents, reflecting the project's impact on upstate New York businesses and communities.

Building the facility will require thousands of skilled craft professionals at peak construction, creating opportunities for union trades, apprentices, local training program graduates, specialty contractors and suppliers. With up to four fabs, Micron’s New York project is the largest private investment in state history and is expected to generate 50,000 jobs in New York, including 9,000 direct Micron jobs.

Building America's memory across the United States

The New York project is the cornerstone of Micron's U.S. investment plan. Micron is also making rapid progress in Idaho, with first wafer output expected in mid-calendar 2027 for the first fab and late calendar 2028 for the second. Earlier this year in Virginia, Micron launched initial production of its 1α (1-alpha) DDR4 technology, supporting customers’ long lifecycle product needs in auto, industrial, medical, aerospace and defense markets.

Together, these projects are expected to create more than 90,000 jobs and advance U.S. economic and national security goals. As Micron makes these investments, the company will remain disciplined in its approach and responsive to the market environment to appropriately align its supply plans.

“This milestone in Central New York shows Micron’s U.S. manufacturing strategy moving from planning to meaningful local impact,” said Manish Bhatia, Micron Executive Vice President of Global Operations. “As we build the capacity, workforce and supplier base needed for the AI era, we are creating opportunities for New York businesses, skilled trades and communities to grow with us. What we are building here will contribute to a thriving semiconductor hub in Central New York, complementing Micron’s existing sites in Idaho and Virginia.”

Investing in the Central New York Community

In honor of America's 250th anniversary, Micron recently announced a $250 million investment in Trump Accounts to reach one million children and families. The company will offer a one-time $250 seed deposit for eligible children in the communities where it operates, including Central New York, as well as an employee match benefit. To date, Micron has also committed more than $50 million to community priorities across Central New York, supporting workforce development, STEM education and other training needs, veterans’ initiatives, housing, transportation, and childcare.

Photos from the event will be available after 3 p.m. ET here.

Kelly Loeffler, Administrator of the U.S. Small Business Administration:

"Micron's massive investment in Central New York – part of a $250 billion investment nationwide – is exactly the kind of bold, American-made commitment that President Trump's agenda was designed to unleash. When a company of Micron's scale puts down roots, it has a powerful effect across our economy – not only by creating 50,000 new jobs and thousands of new work orders for local job creators, but also by strengthening small businesses across America who depend on leading-edge semiconductor technology to fuel every vital industry, from defense to energy. SBA is proud to support the small manufacturers, contractors, and local businesses that will grow alongside Micron's fab as the company advances this Administration’s mission to rebuild American industrial dominance.”

U.S. Chief Technology Officer Dr. Ethan Klein:

"The Trump Administration is committed to achieving unrivaled American leadership in AI, microelectronics, and the full semiconductor supply chain — and milestones like this one show we are turning that commitment into reality. Micron's $250 billion U.S. investments in leading-edge memory manufacturing and R&D will directly power the next generation of American innovation, and we are proud to see that future taking shape right here on American soil."

U.S. Senator Charles E. Schumer:

“Micron’s first concrete pour marks concrete progress towards bringing America’s largest semiconductor manufacturing facility to life right here in Central New York! Micron’s chips are in demand more than ever, and their Central New York project and the 50,000 jobs it’ll create put New York on the global map for advanced chip production. Micron’s total $250 billion U.S. investment is transformative for manufacturing in America and New York. I delivered a $6.1 billion CHIPS grant and billions more in Investment Tax Credit assistance from my CHIPS & Science Law to make this historic project possible. Today, we celebrate a new chapter for American chip manufacturing with Upstate New York leading the way.”

U.S. Congresswoman Claudia Tenney:

“I know how important Micron's investment is to this community — and today's milestone makes that investment tangible. Pouring the first concrete ahead of schedule is a testament to what American workers and American ingenuity can accomplish when Washington opens the path for industry to succeed. By expanding the Advanced Manufacturing Investment Credit through the One Big Beautiful Bill and championing the Working Families Tax Cut Act, Congress has sent a clear signal that the United States is committed to long-term technological leadership and supporting the next generation. Micron's $250 billion investment in making leading-edge memory in the U.S. will create good-paying jobs and strengthen our national security.”

U.S. Congressman John Mannion:

"Pouring the first concrete at Micron's Clay fab — ahead of schedule — is proof that this project is delivering for Central New York. From championing Green CHIPS in the state legislature to fighting for federal investment in Congress, I have been proud to help lay the groundwork for what will become the largest semiconductor manufacturing site in U.S. history, and part of a $250 billion Micron investment across the country. This is an investment in the thousands of workers, families, and businesses of Central New York who will build this facility and help secure America's dominance in the global semiconductor industry for generations to come."

Onondaga County Executive Ryan McMahon:

"Today's milestone is a proud and defining moment for Onondaga County, Central New York, and the country. Pouring the first concrete at Micron's historic New York campus is proof of what this community can achieve when we set ambitious goals, work together, and refuse to slow down. Reaching this milestone months ahead of schedule reflects the grit of the people of Central New York — and the strength of the partnership we have built with Micron. This project to build leading-edge memory locally will reshape the trajectory of our region for generations, and today reminds us that when Onondaga County comes together with purpose, we don't just meet expectations — we exceed them."

Matt Nesbitt, President, Central & Northern New York Building Trades:

“The Central and Northern New York Building and Construction Trades Council could not be more excited for the monumental event today. We are poised and ready for the challenge of building the largest construction project in the history of New York State. The invaluable partnership that our council has forged with Micron to prepare for this historic project is about to be on full display as we build one of the largest chip manufacturing facilities in the United States.”

Justin Driscoll, President & CEO, New York Power Authority:

“Today’s milestone at Micron’s Clay site reflects the growing momentum behind this transformative project. NYPA low-cost power allocations played a vital role in attracting this once-in-a-generation investment that will strengthen New York’s economy, create tens of thousands of good jobs, and cement New York’s role as a global leader in advanced manufacturing.”

David Anderson, President, NY Creates:

"Micron’s announcement that construction is already moving ahead of schedule is exciting for Central New York and for the future of domestic semiconductor manufacturing. This milestone represents tangible progress on a transformational project that will strengthen America’s memory chips leadership and the related supply chain, create thousands of high-tech careers, and generate lasting economic impact across the region. At the same time, NY Creates is proud to partner with Micron on our High NA EUV Lithography Center and the Industrial Manufacturing Technician (IMT) Apprenticeship Program, which advance the capabilities and talent needed to further strengthen the nation’s innovation ecosystem.”

Rob Simpson, Chief Executive Officer, CenterState CEO:

“This is one more important milestone in the foundation we are building for our region's economic resurgence and our country's national security. We are grateful to Micron for their continued partnership and investment in our region and excited to carry this message forward to the global semi-conductor supply chain — Central New York is quickly becoming one of the most important centers for memory and chip manufacturing in the world."

About Micron Technology, Inc.

Micron Technology, Inc. is an industry leader in innovative memory and storage solutions, transforming how the world uses information to enrich life for all. With a relentless focus on our customers, technology leadership and manufacturing and operational excellence, Micron delivers a rich portfolio of high-performance DRAM, NAND and NOR memory and storage products. Every day, the innovations that our people create fuel the data economy, enabling advances in artificial intelligence (AI) and compute-intensive applications that unleash opportunities — from the data center to the intelligent edge and across the client and mobile user experience. To learn more about Micron Technology, Inc. (Nasdaq: MU), visit micron.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding expected acceleration and expansion of construction projects, target U.S.-based DRAM production, anticipated research and development expansion, expected timing of first wafer output, planned manufacturing, supply chain and community investments, job creation and workforce expansion, and expected economic and community impacts. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially. Please refer to the documents Micron files with the Securities and Exchange Commission, specifically its most recent Form 10-K and Form 10-Q. These documents contain and identify important factors that could cause actual results to differ materially from those contained in these forward-looking statements. These certain factors can be found at https://investors.micron.com/risk-factor. Although Micron believes that the expectations reflected in the forward-looking statements are reasonable, Micron cannot guarantee future results, levels of activity, or achievements. Micron is under no duty to update any of the forward-looking statements after the date of this press release to conform these statements to actual results.

© 2026 Micron Technology, Inc. All rights reserved. Information, products, and/or specifications are subject to change without notice. Micron, the Micron logo, and all other Micron trademarks are the property of Micron Technology, Inc. All other trademarks are the property of their respective owners.

Micron Media Relations Contact
Anna Newby 
+1 (262) 385-7065 
[email protected]

Micron Investor Relations Contact 
Satya Kumar 
+1 (408) 450-6199 
[email protected]

Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data

New data compares the diagnostic performance of P-tau217 blood tests with amyloid positron emission tomography (PET) in cognitively unimpaired Alzheimer's disease

Research spanning diagnostics, long-term treatment, disease biology, and patient-centered outcomes reflects Lilly's 35-year commitment to Alzheimer's disease science

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will present 16 abstracts at the 2026 Alzheimer's Association International Conference (AAIC), July 12-15 in London. Three oral presentations anchor the scientific program, with 13 poster presentations spanning imaging science, health economics, real-world prescribing evidence, and patient-centered outcomes, reflecting Lilly's 35-year commitment to answering open questions in Alzheimer's disease.

Key Presentations at AAIC 2026

New Clinical Evidence on Kisunla (donanemab-azbt)

On July 15, a Developing Topics Session, Donanemab in Early Symptomatic Alzheimer's Disease: Evidence to Address Clinical Questions, will present new insights from TRAILBLAZER-ALZ 6 and the TRAILBLAZER-ALZ 2 long-term extension. Findings include new data on safety through modified titration and corticosteroid pretreatment as well as long-term extension evidence on biomarkers and the potential durability of clinical benefit.

Advancing Diagnostics

Also on July 15, Samantha Burnham, Ph.D., senior research scientist, Eli Lilly and Company, will present data showing P-tau217 blood biomarker assays demonstrated strong rule-in performance comparable to amyloid PET for identifying Alzheimer's disease pathology in cognitively unimpaired individuals. Though blood biomarker tests and amyloid PET agents are not currently indicated for use in cognitively unimpaired individuals, the results generate support for a potentially scalable, accessible alternative to specialized imaging in the future.

Advancing Scientific Methodology

On July 13, as the organizer of the Featured Research Session, Lars Raket, Ph.D., Eli Lilly and Company, will deliver an oral presentation on external controls versus internal extrapolation in the TRAILBLAZER-ALZ 2 long-term extension (Room N10). The analysis addresses a key methodological question in Alzheimer's disease research: how long-term outcomes are measured and interpreted in clinical trials, reflecting Lilly's commitment to the scientific rigor that underpins credible long-term evidence generation.

A full list of abstracts appears below. Presentations will be available at www.lilly.com following their scheduled release times.

Abstract Title

Presenter

Presentation
Type/#

Details (Date, Time,
Location, Session Time)

Kisunla (donanemab-azbt)

External Controls vs. Internal
Extrapolation in the
TRAILBLAZER-ALZ 2 Long-
Term Extension

Lars Raket

Featured
Research
Session

7/13/2026

Room: N10

Session: 9-10:30 a.m.

Donanemab in Early
Symptomatic Alzheimer's
Disease: Evidence to
Address Clinical Questions

Nick Fox,

Emel Serap
Monkul Nery,

Hong Wang,

Erin Doty

Developing
Topics Session

7/15/2026

9-10:30 a.m.

Interim Analysis of the
United Kingdom
Donanemab Controlled
Access Programme: Early
Patient Characteristics and
Prescribing Patterns

Krista Schroeder

Poster

7/12/2026

Poster #8953

7:30 a.m.-4:15 p.m.

Exhibit Hall

Diagnostics

Blood Biomarker Assays
Demonstrate Strong Rule-in
Performance for Identifying
Cognitively Unimpaired AD

Samantha
Burnham

Oral

7/15/2026

Room: S11

Session: 8-8:45 a.m.
 

Baseline amyloid and tau
PET characteristics in early
Alzheimer's Disease: Results
from the TRAILRUNNER-ALZ
3 PET Addendum

Ilke Tunali

Poster

7/15/2026

Biomarkers: Neuroimaging,
8 a.m.- 3 p.m.

Exhibit Hall

Evaluation of Diffusion
Tensor Imaging biomarkers
in phase 2 PROSPECT-ALZ
study of Ceperognastat in
early symptomatic
Alzheimer's disease

Ajay Kurani

Poster

7/13/2026
7:30 a.m.-4:15 p.m.

Exhibit Hall

Data-Driven Feature Map
Associating Baseline
Florbetapir-PET Uptake
Patterns to ARIA-E Incidence

Ian Kennedy

Poster

7/13/2026

7:30 a.m.-4:15 p.m.

Exhibit Hall

Regional tau PET Extent to
estimate pathological
volume, capture tau
heterogeneity, and detect
treatment response in
clinical trials

Vikas Kotari

Poster

7/11/2026 and 7/14/2026

Biomarkers: Neuroimaging,
7:30 a.m.-4:15 p.m.

*Will also be presented at
AIC ahead of AAIC*

Cross-sectional evaluation of
diffusion tensor imaging
endpoints using three
clinical trials in Alzheimer's
disease

Diana Otero

Poster

7/13/2026

Biomarkers: Neuroimaging,

7:30 a.m.-4:15 p.m.

Exhibit Hall

Health Economics and Outcomes Research (HEOR)

Drivers of Increased
Healthcare Utilization and
Medicare Payments During
Cognitively Unimpaired
(Preclinical) Alzheimer's
Disease Progression

Zachary Sheff

Poster

7/12/2026

Poster #441

7:30 a.m.-4:15 p.m.

Exhibit Hall

Neurocognitive, Biomarker,
and Health Outcomes in
Those at Risk for Alzheimer's
Disease Symptoms:
ANCHOR-AD Study Design

Nalin Payakachat

Poster

7/14/2026

Poster #9036

7:30 a.m.-4:15 p.m.

Exhibit Hall

Incident institutionalization
rates among Medicare
beneficiaries with
Alzheimer's disease or mild
cognitive impairment

Zachary Sheff

Poster

7/12/2026

Poster # 7262

7:30 a.m.-4:15 p.m.

Exhibit Hall

Risk Algorithms to Predict
Elevated Plasma P-tau217
Status: A Cross-sectional
Analysis

Nalin Payakachat

Poster

7/12/2026

Poster # 2141

7:30 a.m.-4:15 p.m.

Exhibit Hall

Natural Language Processing
(NLP) Algorithms to Identify
Intracerebral Hemorrhage
>1 cm and Amyloid-Related
Imaging Abnormalities
(ARIA) in US Electronic
Medical Records

Krista Schroeder

Poster

7/15/2026

Poster # 8947

7:30 a.m.-4:15 p.m.

Exhibit Hall

About Alzheimer's Disease
By 2030, an estimated 78 million people worldwide are projected to have Alzheimer's disease, rising from approximately 55 million today, from those living with the earliest changes associated with the disease, to those experiencing profound memory loss.¹ The disease begins silently, often decades before any change in memory or thinking, with the accumulation of amyloid plaques in the brain,2 progressing through stages of increasing memory loss, behavioral changes, and growing dependence on caregivers.3

Nearly 4 in 5 Americans say they would want to know if they had Alzheimer's disease before experiencing symptoms or before symptoms interfere with their daily activities.4  

About Kisunla® (donanemab-azbt)
Kisunla is currently approved as an amyloid-targeting treatment for people with mild cognitive impairment as well as people with mild dementia stage of early symptomatic Alzheimer's disease with confirmed amyloid pathology. Kisunla is a humanized monoclonal antibody that targets and reduces insoluble N-truncated pyroglutamate amyloid beta plaques, a defining feature of Alzheimer's disease, and is administered as an intravenous infusion every four weeks. Kisunla can cause serious side effects, including ARIA and infusion-related reactions. Apolipoprotein E ε4 (ApoE ε4) homozygotes have a higher incidence of ARIA, including symptomatic and serious ARIA, and testing for ApoE ε4 status should be performed prior to initiating treatment. Carriers of one or two copies of the ApoE ε4 gene may be at higher risk of developing Alzheimer's disease and experiencing ARIA. Patients should discuss any safety concerns with their healthcare providers.

INDICATION AND SAFETY SUMMARY WITH WARNINGS
Kisunla® (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.  

Warnings - Kisunla can cause Amyloid-Related Imaging Abnormalities or "ARIA." This is a common side effect that does not usually cause any symptoms, but serious symptoms can occur. ARIA can be fatal. ARIA is most commonly seen as temporary swelling in an area or areas of the brain that usually goes away over time. Some people may also have spots of bleeding on the surface of or in the brain and infrequently, larger areas of bleeding in the brain can occur. Although most people do not have symptoms, some people have:  

Headache Dizziness   Nausea  Difficulty
walking Confusion Vision changes Seizures  Some people have a genetic risk factor (homozygous apolipoprotein E ε4 gene carriers) that may cause an increased risk for ARIA. Talk to your healthcare provider about testing to see if you have this risk factor. 

You may be at higher risk of developing bleeding in the brain if you take medicines to reduce blood clots from forming (antithrombotic medicines) while receiving Kisunla. Talk to your healthcare provider to see if you are on any medicines that increase this risk. 

Your healthcare provider will do magnetic resonance imaging (MRI) brain scans before and during your treatment with Kisunla to check you for ARIA. You should carry information that you are receiving Kisunla, which can cause ARIA, and that ARIA symptoms can look like stroke symptoms. Call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the symptoms listed above. 

There are registries that collect information on treatments for Alzheimer's disease. Your healthcare provider can help you become enrolled in these registries.

Warnings - Kisunla can cause serious allergic and infusion-related reactions. Do not receive Kisunla if you have serious allergic reactions to donanemab-azbt or any of the ingredients in Kisunla. Symptoms may include swelling of the face, lips, mouth, or eyelids, problems breathing, hives, chills, irritation of skin, nausea, vomiting, sweating, headache, or chest pain. You will be monitored for at least 30 minutes after you receive Kisunla for any reaction. Tell your healthcare provider right away if you have these symptoms or any reaction during or after a Kisunla infusion.

Other common side effects 

Headache  Tell your healthcare provider right away if you have any side effects. These are not all of the possible side effects of Kisunla. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch. 

Before you receive Kisunla, tell your healthcare provider: 

About all medicines you take, including prescription and over-the-counter medicines, as well as vitamins and herbal supplements. Especially tell your healthcare provider if you have medicines to reduce blood clots from forming (antithrombotic medicines, including aspirin).  About all of your medical conditions including if you are pregnant, breastfeeding, or plan to become pregnant or breastfeed. Kisunla has not been studied in people who were pregnant or breastfeeding. It is not known if Kisunla could harm your unborn or breastfeeding baby.   How to receive Kisunla
Kisunla is a prescription medicine given through an intravenous (IV) infusion using a needle inserted into a vein in your arm. Kisunla is given once every 4 weeks. Each infusion will last about 30 minutes.

Learn more  
For more information about Kisunla, call 1-800-LillyRx (1-800-545-5979) or go to kisunla.lilly.com. 

This summary provides basic information about Kisunla. It does not include all information known about this medicine. Read the information given to you about Kisunla. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Kisunla. Your healthcare provider is the best person to help you decide if Kisunla is right for you.

DN CON BS APP 

Kisunla® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. 

Frequently Asked Questions

How accurate are blood tests for diagnosing Alzheimer's disease? What is P-tau217 and how is it used in Alzheimer's disease diagnosis? How effective is Kisunla in slowing Alzheimer's disease progression? What was presented at the Alzheimer's Association International Conference (AAIC) 2026? About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Kisunla (donanemab-azbt) as a treatment for people with early symptomatic Alzheimer's disease and as a potential treatment for patients with cognitively unimpaired Alzheimer's disease and other conditions and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that Kisunla will receive additional regulatory approvals, or that Kisunla will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. 

References 

Alzheimer's Disease International. 2026 Dementia statistics. https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/. Accessed 24 June 2026.  Sperling RA, Donohue MC, Rissman RA, et al. Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies. J Prev Alzheimers Dis. 2024;11(4):802–813.   Alzheimer's Association. Stages of Alzheimer's. www.alz.org/alzheimers-dementia/stages.  Accessed 24 June 2026.  Alzheimer's Association. 2025 Alzheimer's disease facts and figures. Alzheimers Dement. 2025;21(5):3708–3821.  Refer to:     Gina Goodenough; [email protected] (Media)
                    Michael Czapar; [email protected] (Investors)

SOURCE Eli Lilly and Company

The U.S. plans to spend $1 trillion for defense in 2026, and the 2027 funding request stands at about $1.5 trillion, which would mark the largest year-over-year increase ever if approved. Rising military spending comes amid rising geopolitical tensions, including the U.S.-Iran and Ukraine-Russia conflicts. The U.S. is also looking to modernize the military and bolster the defense industrial base and has allocated capital for space-based missile defense initiatives.

Defense contractors should benefit from growing order books and long-term contracts that provide insight into future earnings. Against this capital-intensive backdrop, defense stocks Lockheed Martin (LMT 1.21%) and RTX Corporation (RTX 0.17%) stand out as beneficiaries due to their strong positions in the industry. Here's what investors need to know.

Image source: Getty Images.

Lockheed Martin's growing platform makes it a defense spending winner Lockheed Martin is a behemoth in the defense industry, boasting a backlog exceeding $186 billion from long-term government contracts. The company has a broad portfolio of offerings, anchored by its flagship F-35 Lightning II jet fighter program, which provides a strong moat that translates into predictable, long-term revenue.

Its F-35 program is projected to cost $2.1 trillion during its 94-year lifecycle and generate roughly a third of Lockheed's revenue. The size and stability of this long-term program help buffer Lockheed's earnings against economic recessions and market volatility and lock in long-term revenue from both jet sales and aftermarket services, including maintenance, repairs, upgrades, and pilot training.

Today's Change

(

-1.21

%) $

-6.38

Current Price

$

521.58

In addition to the F-35, Lockheed holds a strong position in high-altitude missile defense, serving as the sole prime contractor for the Terminal High Altitude Area Defense (THAAD) weapon system. In late June, the U.S. government formally awarded it a contract for as much as $35 billion over seven years to quadruple the production of its THAAD interceptors.

In another major move, on July 6, Lockheed Martin signed an agreement to acquire Ultra Maritime Solutions for $3.45 billion, giving it a strong foothold in the rapidly growing undersea weapons market. Lockheed acquired the company from Advent International and now controls key undersea defense technologies, including sonobuoys for submarine detection, torpedo defense systems, and uncrewed underwater vehicles.

As military spending ramps up, Lockheed Martin is a top defense contractor that stands to benefit. Its position provides it with steady, predictable revenue that powers steady long-term growth. The company has raised its dividend for 23 consecutive years and yields about 2.6%, making Lockheed a top pick for investors looking to capitalize on growing global defense budgets.

RTX combines defense upside with commercial aerospace stability RTX Corporation boasts an even more impressive backlog of $271 billion, up 25% during the past year. RTX's business spans commercial aerospace and defense, operating three segments: Raytheon, Pratt & Whitney, and Collins Aerospace. As a result, RTX has a more diverse portfolio than pure-play military contractors, balancing defense awards with commercial contracts. Like Lockheed, RTX benefits from its huge backlog that ensures long-term revenue consistency years down the road.

Through Pratt & Whitney, RTX provides aircraft propulsion systems for both commercial aircraft and Lockheed Martin's F-35 Lightning II Joint Strike Fighter, generating high-margin recurring aftermarket revenue. Through Raytheon, the company manufactures the Patriot air defense system, advanced missiles, naval and land radars, and directed-energy weapons. The segment accounts for $109 billion of its enormous backlog.

Today's Change

(

-0.17

%) $

-0.33

Current Price

$

194.58

The company is seeing robust demand for its air defense systems, and on July 7, it announced it would partner with European manufacturers in Germany and the Netherlands to double the global production capacity for its Stinger surface-to-air missiles. In addition, in late June, it announced a $1.1 billion contract modification to replenish American stockpiles and arm allied nations with tactical missiles.

RTX's large backlog ensures rising earnings in the years ahead, and the company stands to benefit from growing military budgets and long-term demand for aftermarket services through its aerospace business, making it another top defense stock for investors to consider scooping up today.

 Expands MARA's digital infrastructure platform with access to approximately 2 GW of power capacity

HIF to retain minority ownership in the project

Thousands of jobs expected for Texas

MIAMI, FL and HOUSTON, TX, July 09, 2026 (GLOBE NEWSWIRE) -- MARA Holdings, Inc. (NASDAQ: MARA) (“MARA”), a leading energy and digital infrastructure company, and HIF USA LLC (“HIF”), a leading energy and sustainable fuels company, today announced that they have entered into a definitive agreement under which MARA will acquire from HIF a large-scale powered land site in Matagorda County, Texas, approximately 90 miles southwest of Houston. HIF will continue its advanced fuels development plans on other sites.

The site encompasses more than 1,200 acres and is expected to provide access to up to an initial 1 GW of grid capacity by October 2027 and up to 2 GW by April 2028. The site is well positioned to support next-generation, efficient digital infrastructure development, and has already received interest from potential High-Performance Computing (“HPC”) tenants. MARA intends to develop the site through its previously announced partnership with Starwood Digital Ventures as a large-scale digital infrastructure campus capable of supporting high-performance computing workloads, as well as flexible compute operations, including Bitcoin mining. Upon execution of a lease with an HPC tenant, HIF will retain a minority ownership interest in the project.

The transaction enables HIF to unlock value from infrastructure assets while maintaining participation in the site’s future development and supporting its broader advanced fuels strategy.

Upon full energization, the site is expected to more than double MARA's potential power capacity to approximately 4.8 GW across its portfolio (including the anticipated close of MARA’s previously announced agreement to acquire Long Ridge Energy & Power), further strengthening MARA's position as a developer and operator of large-scale digital infrastructure.

“This transaction advances our strategy of securing strategically located infrastructure assets capable of supporting high-performance compute and bitcoin workloads,” said Fred Thiel, MARA's chairman and CEO. “As demand for digital infrastructure continues to grow, we believe sites with access to reliable, scalable power will become increasingly valuable. This acquisition meaningfully expands our long-term development pipeline and strengthens our ability to support high-performance compute and maximize the value of that power over time. We look forward to working with our partners at the site to deliver on the project buildout and drive long-term value for all our stakeholders.”

Renato Pereira, CEO of HIF USA, said, “We are pleased to welcome MARA to our long-term partnership with Matagorda County, accelerating our commitment to economic investment and jobs for Texans. The development of this digital infrastructure serves as a powerful economic anchor to strengthen Matagorda County and create local career opportunities for a prosperous future. We have given Notice to Proceed for construction on the switchyard to connect the site to the grid. We continue work on our advanced fuels facilities on other sites we control in Texas and worldwide to provide new sources of secure energy supply to meet rapidly growing global demand.”

Site Development Details

Phased construction of the digital infrastructure campus is expected to begin in 2026, contingent upon regulatory approvals.

By combining MARA's expertise in securing and managing large-scale power loads, Starwood Digital Ventures' world-class experience developing and operating data centers, and HIF's history in Matagorda, MARA believes the site is well positioned to support future digital infrastructure opportunities and create long-term value for customers, local communities, and shareholders.

MARA has a proven track record of investing in the communities where it operates while supporting grid reliability and local economic growth. To date, MARA has invested more than $1.2 billion in Texas. MARA intends to continue investing significantly to develop a premier digital infrastructure campus that is expected to support thousands of construction and permanent full-time jobs upon completion.

About MARA

MARA (NASDAQ: MARA) deploys digital energy technologies to advance the world’s energy systems. Harnessing the power of compute, MARA transforms excess energy into digital capital, balancing the grid and accelerating the deployment of critical infrastructure. Building on its expertise to redefine the future of energy, MARA develops technologies that reduce the energy demands of high-performance computing applications, from AI to the edge.

About HIF Global

HIF Global is a world leading e-Fuels company developing large scale infrastructure projects to recycle captured CO₂ and produce synthetic fuels for existing engines. The name HIF reflects the company’s mission: to produce Highly Innovative Fuels that contribute to global energy security. HIF already produces e-Fuels at its HIF Haru Oni facility in southern Chile and is developing large scale projects in the United States, Uruguay, Brazil, Australia, and Chile. For more information, visit www.hifglobal.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. All statements, other than statements of historical fact, included in this press release are forward-looking statements. The words “may,” “will,” “could,” “anticipate,” “expect,” “intend,” “believe,” “continue,” “target” and similar expressions or variations or negatives of these words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements include, among other things, statements related to the occurrence of any event, change or other circumstance that could give rise to the exercise of any return or forfeiture right under, the purchase agreement entered into in connection with MARA’s acquisition of the site; MARA’s planned development of the site as a digital infrastructure campus; the expected power capacity (including as a result of the agreement to acquire Long Ridge Energy & Power), scalability and performance of the site; the anticipated ability to commercialize the site’s power capacity for high-performance compute and bitcoin workloads; the number of construction and other jobs anticipated to be created; and the anticipated benefits of the transaction to MARA. Such forward-looking statements are based on management’s current expectations about future events as of the date hereof and involve many risks and uncertainties that could cause MARA’s actual results to differ materially from those expressed or implied in these forward-looking statements. Subsequent events and developments, including actual results or changes in MARA’s assumptions, may cause MARA’s views to change. Readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements included herein are expressly qualified in their entirety by these cautionary statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including uncertainties related to market conditions, the risk that the transaction disrupts MARA’s current plans and operations or diverts management’s attention from its ongoing business, the effect of the announcement of the transaction on the ability of MARA to retain and hire key personnel and maintain relationships with others with whom it does business, the effect of the announcement of the transaction on MARA’s operating results and business generally and the other factors discussed in the “Risk Factors” section of MARA’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) and the risks described in other filings that MARA may make from time to time with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and MARA specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required by applicable law.

MARA Company Contact:
Telephone: 800-804-1690
Email: [email protected]

MARA Media Contact:
Email: [email protected]

HIF USA Media Contact:
Liza Luter
Email: [email protected]
Phone: 214-601-7474

NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- via NetworkNewsWire (“NNW”) — Wrap Technologies Inc. (NASDAQ: WRAP) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “Federal Ruling Changes Economics of Nonlethal Law Enforcement,” please visit: https://ibn.fm/SQDXI

American law enforcement is in the middle of a legal and cultural reckoning over use of force. Courts are demanding more from officers before they reach for traditional weapons, and the Supreme Court’s unanimous 2025 ruling in Barnes v. Felix has made that demand structurally unavoidable: Every use-of-force decision must now be evaluated against the full context of the encounter, not just the moment it occurred. That legal shift is creating real procurement demand for tools that give officers options earlier in an encounter, before the situation reaches the force threshold that generates liability. 

Wrap Technologies Inc. builds exactly those tools, and last week the company received a ruling from the Bureau of Alcohol, Tobacco, Firearms and Explosives (“ATF”) that may be the single most consequential development in its commercial history: ATF Ruling 2026-2 formally classified the BolaWrap(R) 150 as an instrument of restraint — not a firearm, not a weapon — under both the Gun Control Act and the National Firearms Act. The ruling strengthens Wrap Technologies’ position among other tech leaders operating in the global public-safety space.

About Wrap Technologies Inc.

Wrap Technologies is a global leader in innovative public safety technologies and non-lethal tools, delivering cutting-edge technology with exceptional people to address the complex, modern-day challenges facing public-safety organizations.

WRAP’s complete public-safety portfolio includes the non-lethal BolaWrap(R) 150 device, Wrap Reality(R) immersive training platform, WrapVision(TM) body-worn camera system, WrapTactics(TM) training programs, and next-generation C-UAS solutions such as PAN-DA and the 1KC Kinetic Anti-Drone Cassette, all of which supports the company’s mission to provide safer, scalable and cost-effective technologies for public safety, defense and critical infrastructure markets.

With a growing demand for non-lethal tools and techniques to create time, distance and tactical advantage in noncriminal calls, Wrap’s BolaWrap 150 incorporates a multisensory distraction of sight and sound as a first response, followed by a non-lethal restraint if further escalation is required. This approach reduces the risk of injury to officers, subjects, and the community.

Wrap’s BolaWrap 150 solution is intended to provide law enforcement with a safer choice for nearly every phase of a critical incident. This innovative, patented device deploys a multi-sensory, cognitive disruption to expand the pre-escalation period and gives officers the advantage and critical time to manage non-compliant subjects before resorting to higher-force options. The BolaWrap 150 is not pain-based compliance. It does not shoot, strike, shock or incapacitate; instead, it helps officers strategically operate pre-escalation on the force continuum, reducing the risk of injury to both officers and subjects. Used by more than 1,000 agencies across the United States and in 60 additional countries, BolaWrap is backed by training certified by the International Association of Directors of Law Enforcement Standards and Training (“IADLEST”), reinforcing Wrap’s commitment to public safety through cutting-edge technology and expert training.

WrapReality(TM) VR is a fully immersive training simulator to enhance decision-making under stress.
As a comprehensive public-safety training platform, it provides first responders with realistic, interactive scenarios that reflect the evolving challenges of modern law enforcement. By offering a growing library of real-world situations, WrapReality is intended to equip officers with the skills and confidence to navigate high stakes encounters effectively, which we believe leads to safer outcomes for both responders and the communities they serve.

WrapVision is an all-new body-worn camera and evidence management system built for efficiency.
Designed for efficiency, security, and transparency to meet the rigorous demands of modern law enforcement, WrapVision captures, stores and helps manage digital evidence, ensuring operational security, regulatory compliance and enhanced video picture quality and field of view.

The WrapVision camera, powered by IONODES, boasts streamlined cloud integration and final North American assembly, with a critical made-in-America roadmap projected for early 2026. This track helps ensure data integrity and helps eliminate critical concerns over unauthorized access or foreign surveillance risks.

NOTE TO INVESTORS: The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP

For more information about Wrap Technologies, visit the company’s website at www.Wrap.com.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness.
NNW is where breaking news, insightful content and actionable information converge.

For more information, please visit www.NetworkNewsWire.com

Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: http://www.nnw.fm/Disclaimer

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

NetworkNewsWire is powered by IBN

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

FREMONT, CA / ACCESS Newswire / July 9, 2026 / Aehr Test Systems (NASDAQ:AEHR), a leading provider of test and burn-in solutions for semiconductor devices used in artificial intelligence (AI), silicon photonics, data center, automotive, and industrial applications, today announced it has received an additional follow-on production order from its lead silicon photonics customer for a fully automated FOX-XP® wafer-level burn-in (WLBI) system. The system will support high-volume production burn-in of silicon photonics devices used in AI optical interconnect and hyperscale data center applications.

The order includes Aehr's turnkey FOX-XP multi-wafer WLBI system configured to test up to nine 300mm wafers in parallel together with the fully automated FOX WaferPak® AutoAligner™, enabling automated, high-volume production burn-in with hands-free operation when integrated with an automated wafer handler.

The customer is developing advanced silicon photonics devices used in next-generation optical interconnects and optical I/O architectures for hyperscale AI and cloud data centers and advanced packaging of AI processors and high-performance computing (HPC) devices. These silicon photonics devices enable dramatically higher bandwidth and lower power communication between AI processors, memory, switches, and networking equipment, addressing one of the industry's most significant bottlenecks as AI infrastructure continues to scale. Industry leaders across the AI ecosystem have increasingly identified silicon photonics and optical I/O as key enabling technologies for future AI clusters, rack-scale computing, and chip-to-chip communications to permanently replace copper interconnects that are approaching their practical performance and power limits.

This customer took delivery of its first FOX-XP with fully automated WaferPak Aligner production system in fiscal 2026. The system has now been successfully installed and demonstrated fully automated, hands-free operation integrated with the customer's automated wafer handling equipment and an automated guided vehicle for 300mm wafer FOUP movement. This represents an important production milestone as the customer ramps up manufacturing of its silicon photonics products.

"The successful installation and production qualification of our first fully-automated system with this customer represents another important milestone in our long-term relationship with them," said Gayn Erickson, President and CEO of Aehr Test Systems. "Demonstrating fully hands-free production operation with our integrated FOX-XP platform and automated wafer handling validates not only our technology, but also our ability to support customers as they transition from engineering qualification into high-volume manufacturing.

"We are very pleased to receive this additional follow-on production order early in our new fiscal year. We believe this order reflects the customer's continued confidence in Aehr's FOX-XP platform and represents an encouraging start to fiscal 2027. As AI infrastructure evolves toward optical interconnects and optical I/O, we believe Aehr is well-positioned to support customers that require cost-effective, high-throughput WLBI and stabilization."

Demand for silicon photonics continues to accelerate as hyperscale AI infrastructure expands. Major technology companies and AI infrastructure providers are increasingly adopting optical interconnect technologies to overcome the bandwidth, latency, and power limitations of traditional electrical interconnects. Industry forecasts anticipate significant growth in silicon photonics deployments over the coming years as optical communication moves closer to AI processors and ultimately onto processor packages through optical I/O architectures.

Aehr's FOX-XP platform is designed for high-power wafer-level test and burn-in of advanced semiconductor devices, including silicon photonics integrated circuits, AI processors, power semiconductors, memory devices, sensors, and other leading-edge semiconductor technologies. The FOX-XP system enables parallel burn-in and test of up to nine wafers simultaneously and, when combined with the FOX WaferPak AutoAligner, provides a fully automated production solution that significantly reduces handling time while improving throughput, repeatability, and manufacturing efficiency. The platform utilizes Aehr's proprietary FOX WaferPak Contactors, allowing full-wafer electrical contact and burn-in before singulation to identify infant mortality failures, improve long-term reliability, and lower overall manufacturing costs.

About Aehr Test Systems

Headquartered in Fremont, California, Aehr Test Systems is a leading provider of test solutions for testing, burning-in, and stabilizing semiconductor devices in wafer-level, singulated die, and package-level form, and has installed thousands of systems worldwide. Increasing quality, reliability, safety, and security needs of semiconductors used across multiple applications, including advanced artificial intelligence (AI) processors, silicon photonics, data and telecommunications infrastructure, electric vehicles, electric vehicle charging infrastructure, solar and wind power, computing, and solid-state memory and storage are driving additional test requirements, incremental capacity needs, and new opportunities for Aehr's products and solutions. Aehr has developed and introduced several innovative products including the FOX-PTM families of test and burn-in systems and FOX WaferPakTM Aligner, FOX WaferPak Contactor, FOX DiePak® Carrier and FOX DiePak Loader. The FOX-XP and FOX-NP systems are full-wafer contact and singulated die/module test and burn-in systems that can test, burn-in, and stabilize a wide range of devices such as leading-edge silicon carbide-based and other power semiconductors, 2D and 3D sensors used in mobile phones, tablets, and other computing devices, memory semiconductors, processors, microcontrollers, systems-on-a-chip, and photonics and integrated optical devices. The FOX-CP system is a low-cost single-wafer compact test solution for logic, memory and photonic devices and the newest addition to the FOX-P product family. The FOX WaferPak Contactor contains a unique full-wafer contactor capable of testing wafers up to 300mm that enables IC manufacturers to perform test, burn-in, and stabilization of full wafers on the FOX-P systems. The FOX DiePak Carrier allows testing, burning in, and stabilization of singulated bare die and modules up to 1024 devices in parallel per DiePak on the FOX-NP and FOX-XP systems up to nine DiePaks at a time. Acquired through its acquisition of Incal Technology, Inc., Aehr's new line of high-power package-level reliability/burn-in test solutions for AI semiconductor manufacturers, including its ultra-high-power Sonoma family of test solutions for AI accelerators, GPUs, and high-performance computing (HPC) processors, position Aehr within the rapidly growing AI market as a turnkey provider of reliability and testing that span from engineering to high volume production. For more information, please visit Aehr Test Systems' website at www.aehr.com.

Safe Harbor Statement

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or Aehr's future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "going to," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these words or other similar terms or expressions that concern Aehr's expectations, strategy, priorities, plans, or intentions. Forward-looking statements in this press release include, but are not limited to, future requirements and orders of Aehr's new and existing customers; Aehr's ability to receive orders and generate revenue in the future, as well as Aehr's beliefs regarding the factors impacting the foregoing, including the growth of the markets referred to herein; Aehr's ability to integrate Incal efficiently; and the timing and extent to which the acquisition is accretive. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in Aehr's recent Form 10-K, 10-Q and other reports filed from time to time with the Securities and Exchange Commission. Aehr disclaims any obligation to update information contained in any forward-looking statement to reflect events or circumstances occurring after the date of this press release.

# # #

Aehr Test Systems

PondelWilkinson, Inc.

Vernon Rogers

Todd Kehrli or Jim Byers

EVP of Sales & Marketing

Analyst/Investor Contact

[email protected]

[email protected]

[email protected]

SOURCE: Aehr Test Systems

Cognizant's Frontier workforce model to create the human infrastructure that turns AI investment into enterprise outcomes Backed by decades of running technology and operations at enterprise scale, Cognizant's human capital operating model embeds outcome-owning Frontier talent inside client operations Cognizant Frontier talent operates across any cloud, any model to help close the gap between AI capability and enterprise results , /PRNewswire/ -- Cognizant (Nasdaq: CTSH), a leading AI Builder and technology services provider, today announced it was committing to scaling its Frontier-certified workforce, the human and operational infrastructure enterprises need to convert AI capability into measurable business results, to 5,000 Frontier Certified Engineers and 10,000 Frontier Business Operators.

Cognizant's people investment will yield its first cohort, which will be both Frontier-assessed and deployment-ready, by fourth quarter, 2026. Cognizant also plans to augment its own Frontier talent pipeline through annual direct hires of Frontier-native talent from American and global universities.

This human capital investment is focused on solving an urgent problem facing enterprises today: most organizations have spent more on AI than on any technology in a generation, and most have little to show for it. Cognizant measures the gap between what AI can deliver and what enterprises actually realize at $4.5 trillion. That gap is not a compute problem. It is a people and process problem, and it will not be closed by provisioning more infrastructure. The required investment is skilling and deploying more Frontier-ready talent into client-oriented delivery to help clients realize a return on their technology investment.

"Closing the AI outcome gap demands talent who not only understands a client's industry deeply but can also reimagine the way work is structured and take end-to-end responsibility for delivering results in collaboration with clients, on any model or cloud the client selects," said Cognizant CEO Ravi Kumar S. "That is what a Frontier workforce does. By taking accountability for outcomes rather than stopping at technology deployment, we can help clients accelerate measurable results while managing risk. Cognizant's industry context and experience position us uniquely to unlock the value that has remained out of reach during this shift toward outcome-based delivery and a new chapter in human capital."

Cognizant's Frontier workforce is model- and cloud-agnostic by design. Its teams build an organization's unique context into whatever stack the client has already chosen, across a partnership footprint that spans Anthropic, OpenAI, Microsoft, Google, AWS, NVIDIA, Salesforce, and ServiceNow. The result is durable capability designed for enterprise ownership and portability across environments, otherwise known as solutions that are geared towards the problems being experienced by our client, not the closest thing a proprietary platform can accomplish.

"AI has exposed 93% of jobs to change, and the associated labor value remains untapped because the workforce architecture built for a pre-AI world cannot capture it. So we rebuilt the architecture for the world we are in now," said Cognizant Chief People Officer, Kathy Diaz. "Industry domain depth is a core strength of Cognizant, and we bring enterprise-scale experience across technology, processes and operations. We know how to take these powerful frontier tools and turn them into real business value, and we are training our workforce to do it at scale."

Cognizant Chief Learning Officer, Thiru Arohi said: "We are developing a new professional identity for the AI era. We are investing in the infrastructure behind this identity: the Academy, the assessment architecture, the certification pathway, and the talent pipeline from campus to senior practitioner. What we are scaling is not headcount, but a workforce capable of closing the outcome gap that no model, platform, or deployment engineer can close alone."

This Frontier model is anchored in six principles: interdisciplinary capability; a direct linkage to customer value; building, deploying, or working alongside agents as routine; end-to-end accountability; delivery through a small operational pod; and a single, unified Cognizant experience for the client. The workforce will be organized as a single premium job family of seven roles across two complementary tracks, Frontier Certified Engineers and Frontier Business Operators:

Frontier Certified Engineers: Frontier Certified Engineers architect and build agentic systems, engineer the retrieval and context layers that keep those systems grounded in domain reality, and orchestrate multi-agent pipelines into live production, remaining accountable for every system they deploy, including ongoing monitoring, tuning and improvement cycles that follow go-live. They are where industry domain expertise, full-stack AI engineering and production accountability converge in a single practitioner. They enter a client environment already fluent in its regulatory constraints, operational failure modes and business logic, and use that fluency to determine not just what AI can do, but what it should do, and how it must be governed to be trusted in alignment with client requirements. Frontier Business Operators: Frontier Business Operators are responsible for delivering operational outcomes in collaboration with client stakeholders in environments where the workforce is simultaneously human and digital, managing agent fleets and human teams against a committed outcome, in real time, with no separation between the two. Their edge is not technical configuration; it is the judgment that comes from having run the operations floors, claims pipelines, and service workflows that AI agents are now being asked to take on. They know how to feed every exception and override back into agent calibration, so the system is continuously refined to improve reliability over time. What sets these roles apart from being forward deployed engineers is permanence, accountability and something that cannot be trained overnight: Cognizant's deep industry domain expertise and the hard-won experience of an AI builder running enterprise operations at scale. The model is already live — a two-person Engineer-and-Operator pod recently reimagined a large food service company's account-management workflow into seventeen production AI agents, reclaiming roughly eleven hours per account manager each week while cutting handoff cycles by about 60 percent and nearly tripling their revenue per engagement.

Underpinning the commitment is a model built to scale and to reach the client. Cognizant stands up local capacity inside client clusters so certified pods deploy close to the work they own, while its global capability centers supply the talent base behind them. The elevation funnel narrows at each stage: from a broad base of AI-fluency skilling across hundreds of thousands of associates, through structured AI-Bridge programs to 40,000 in Frontier certification, credentialed directly by the frontier-model companies, including GitHub Copilot, Google Gemini, Anthropic's Claude, and OpenAI's Codex. Today's announced investment will expand Cognizant's SkillSpring™ capacity, deliver AI-fluency and responsible-AI training across the workforce, and fund embedded client engagements worldwide.

For enterprises, the payoff is measured where it matters most: AI investment converted into business results, delivering value from the technology stack they already run, with accountability through an AI builder firm that lasts well beyond go-live. In committing to the people who deliver those outcomes, Cognizant is making a strategic bet that the defining edge of the AI era will be human and operational, and positioning its clients to pursue the financial return from their technology investment which has eluded them. That is the future of AI: not just capability, but outcomes that endure.

About Cognizant

Cognizant (Nasdaq: CTSH) is an AI Builder and technology services provider, bridging the gap between AI investment and enterprise value by building full-stack AI solutions for our clients. Our deep industry, process and engineering expertise enables us to build an organization's unique context into technology systems that amplify human potential, drive tangible outcomes and keep global enterprises ahead in a fast-changing world. See how at www.cognizant.ai or @cognizant.

For more information, contact:

SOURCE Cognizant Technology Solutions

DENVER, July 09, 2026 (GLOBE NEWSWIRE) -- The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a leader in the Nutritional Snacking Category, today reported financial results for the thirteen and thirty-nine weeks ended May 30, 2026. Third Quarter Summary: (1) Net sales of $357.0 million versus $381.0 million Net loss of $52.0 million versus net income of $41.1 million Loss per diluted share of $0.58 versus earnings per diluted share of $0.40 Adjusted Diluted EPS (2) of $0.42 versus $0.51 Adjusted EBITDA (3) of $57.2 million versus $73.9 million Updating Fiscal Year 2026 (4) Outlook: Net sales expected to range between $1.345 and $1.355 billion, or a decline of roughly 7% to 6% year-over-year Gross margins expected to decline approximately 375 basis points year-over-year Adjusted EBITDA expected to range between $220 and $225 million, or -21% to -19% year-over-year “Our third quarter results reflect initial steps against the turnaround priorities we outlined last quarter.

Visitors walk near a logo of Google at Bharat Mandapam, one of the venues for AI Impact Summit, in New Delhi, India, February 17, 2026. REUTERS/Bhawika Chhabra/File Photo Purchase Licensing Rights, opens new tab

SummaryCompaniesGoogle counts India as a key growth market for search, adsCourt said Google ad platform was allowing trademark breachGoogle says ruling has major consequences for digital ad marketNEW DELHI, July 9 (Reuters) - Google (GOOGL.O), opens new tab has challenged an Indian ​court ruling that it infringed on a company's trademark rights by allowing rivals to use its ‌name as an advertising keyword, arguing the decision will hurt consumers, documents reviewed by Reuters show.

The May decision could reshape the online ads market in a country where Google last year earned $4.1 billion in gross advertising revenue but where it is also facing a raft of ​antitrust cases and court battles.

The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.

To ensure their ads are promoted by Google and target the right customers, ​companies bid on keywords that online consumers type into the search engine.

Indian bathroom fittings maker ⁠Hindware, however, accused its rivals of purchasing keywords related to its brand on the Google ads platform, so that ​their websites appear at the top of searches when consumers typed in "Hindware".

The Delhi High Court ruled against Google in the ​case, ordering it to pay damages of $31,600 and other litigation costs.

In its 4,761-page challenge, which is not public but was reviewed by Reuters, Google said the decision makes India the "sole outlier" among global jurisdictions "with serious consequences for the digital advertising industry, online consumer choice, ​and competitive markets."

Researchers have observed that consumers may search for a brand in order to identify and assess alternatives, ​Google wrote in the July 7 filing, arguing the ruling will effectively grant trademark owners a "monopoly over advertising space to the detriment ‌of consumers."

In ⁠a response to a Reuters request for comment, Google confirmed it is appealing the order, which it said "diverges from established legal precedents in India". It added that its ads policies reflect standard practices that enable competition.

Google India's appeal will be heard in the coming days.

GOOGLE SELLING SOMETHING IT DOESN'T OWN, JUDGE SAYSIf upheld, Indian lawyers and tech experts ​say the original ruling will ​have wide-ranging ramifications for how ⁠the online ads market operates.

Indian matchmaking service Shaadi.com, for example, said that it would change the economics of online ads for millions of businesses that were suffering when their ​competitors bid on their name and Google took a fee.

Justice Mini Pushkarna noted in ​the decision in ⁠May that Google could not be permitted to shrug off responsibility after making a tool available that leads to trademark infringement.

"Google has attempted to sell something that it simply does not own," Pushkarna wrote.

Google's appeal rejects the position that it has ⁠infringed ​on trademarks, arguing that "a keyword is merely used as an internal and ​backend trigger to display an ad" and is simply "making advertising space available".

Google also faces antitrust cases in India as well as legal challenges over AI ​training and stricter-than-ever content takedown regulations that began applying to tech companies from February.

Reporting by Aditya Kalra; Editing by Joe Bavier

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Aditya Kalra is the Company News Editor for Reuters in India, overseeing business coverage and reporting stories on some of the world's biggest companies. He joined Reuters in 2008 and has in recent years written stories on challenges and strategies of a wide array of companies -- from Amazon, Google and Walmart to Xiaomi, Starbucks and Reliance. He also extensively works on deeply-reported and investigative business stories.

Latest IBM Bob Updates Help Enterprises Deliver Production-Ready Software Fast IBM Bob is Built to Optimize the Cost of AI-Driven Development Beyond the Model IBM Bob Now Offers Pre-Built, Customizable Enterprise Workflows for IBM Z, IBM i, Plus Java Modernization , /PRNewswire/ -- Today, IBM (NYSE: IBM) announced major updates to IBM Bob, its agentic software development platform, including new multi-agent capabilities, built-in AI cost and use analytics, and pre-built, specialized workflows for modernizing enterprise systems.

Now that organizations are using AI to write massive amounts of code, their software development challenges have moved to other parts of the process with 85% of DevSecOps professionals surveyed agreeing that AI has shifted the bottleneck from writing code to reviewing and validating it.1 IBM Bob is architected to bring AI capabilities wherever software engineering work happens. Rather than limiting AI to a single development interface for isolated tasks, Bob provides a unified foundation for teams to coordinate across the software development lifecycle.

For example, engineers at Jack Henry, a leading financial services and banking technology provider, were facing challenges maintaining and evolving a large RPG codebase as its application portfolio expanded in size and complexity. "Using IBM Bob," explained Kevin Sligar, Chief Technical Architect at Jack Henry. "Our developers are able to accelerate RPG development workflows, improve code quality, and gain deeper insights into decades of accumulated system knowledge while gaining efficiency in enhancement efforts."

Many enterprise engineers are manually choosing models, trying to balancing cost versus performance, and still ending up with inconsistent outcomes and unpredictable spend. Bob can now optimize across the execution system, not just model selection. Bob matches models to tasks, coordinates AI execution across agents, and provides organizations with visibility into productivity, quality, performance, and cost through the newly launched Bobalytics, to help enterprises optimize AI at scale.

"Bob is the platform enterprise customers have been asking for," said Neel Sundaresan, GM, Automation and AI, IBM. "The bar for enterprise AI is no longer a better coding assistant. It's an end-to-end agentic development partner that works inside any system development teams already use, with the governance, security, and cost controls enterprises require. We built Bob to solve the problems enterprises actually have, and the updates we're announcing today are the foundation for everything that comes next."

Engineering teams also encounter unique challenges as they move beyond code generation and apply AI to larger, more complex work like updating legacy applications or modernizing IBM Z, IBM i, and Java environments.

Blue Pearl, a cloud solutions and consulting services company, has successfully used IBM Bob for this type of complex project. "We introduced IBM Bob to a legacy modernization program, an effort originally projected to take nine months with 14 engineers was completed in just three days," said Saireshan Govender, Group CEO of Blue Pearl. "The most powerful outcome wasn't the speed – it was the combination of operational efficiency, cost optimization, and real-world results we could trust and build on."

AI output can vary depending on how the work is done, which can create significant issues for these types of high-stakes, multi-phase projects. Structured, repeatable workflows help reduce that variability so teams can deliver reliable, auditable results at enterprise scale.

IBM Bob now has pre-built workflows available that teams can customize and extend for their own environments to ensure outcomes are consistent and auditable, regardless of who runs it. IBM Bob Premium Packages for IBM Z, IBM i, and Java Modernization, are each opinionated workflows built on decades of IBM's domain experience that optimize AI for enterprise teams that need to do large-scale modernization.

What's New In IBM Bob:

Built-in usage visibility and cost optimization: Users can now access Bobalytics, a new feature that helps them monitor consumption, allocate resources and maintain oversight so they can scale AI according to their internal mandates. Parallel, model-native tool calling: Bob now allows models to request several tools in one turn and run them together. Subagents manage context at scale: Every exploratory step an AI takes, whether it's file reads, searches, or function traces, can bloat the context window and drive up cost. Now Bob subagents handle complex work in an isolated context, to deliver fast responses while helping manage cost. The latest version of IBM Bob is available for download at bob.ibm.com/download and for more details on the new capabilities and features, visit: https://bob.ibm.com/blog/bob-v2-release-announcement.

Now Available: IBM Bob Premium Packages

IBM has spent decades at the center of enterprise modernization across mainframes, IBM i systems, and Java codebases that global businesses run on. Bob's first three premium packages translate IBM's institutional knowledge into AI-native workflows that are structured, repeatable, auditable and purpose-built for the environments other tools weren't designed to handle.

Premium packages available now include:

IBM Z: Mainframe environments sit at the core of global banking, insurance and commerce, and have historically been the hardest places for AI to help. Bob now addresses this by bringing AI-native application modernization to IBM Z for the first time with COBOL and PL/I modernization and JCL analysis. For more details on Premium Package for IBM Z, visit: https://www.ibm.com/new/announcements/announcing-the-ibm-bob-premium-package-for-z IBM i: IBM i has powered mission-critical operations at enterprises worldwide for decades. Bob is bringing AI-native development to these environments for the first time, with remote file system integration, IBM i-specific modes and tools, and workflows built around the operational patterns of IBM i shops. For more details on Premium Package for IBMI i, visit: https://www.ibm.com/new/announcements/introducing-the-ibm-bob-premium-package-for-i Java Modernization: Enterprise Java portfolios remain some of the largest and most complex modernization challenges in today's software landscape. Bob delivers AI-guided workflows for Java modernization, including migration to Java 25, large-scale refactoring and dependency analysis at scale, in a structured and repeatable manner. For more details on Premium Package for Java Modernization, visit: https://www.ibm.com/new/announcements/announcing-ibm-bob-premium-package-for-java-modernization About IBM

IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.

Media contact: 

Rebecca Neufeld
IBM
[email protected] 

1

GitLab. (2026). The 2026 AI Accountability Report.

SOURCE IBM

Chip stocks were set for a rebound on Thursday as investors stepped back into the AI hardware trade after two brutal sessions of profit-taking.

Micron rose 3.5% in premarket trading to $982.05, while AMD and Intel also gained over 2.5% after recent Wall Street target hikes helped restore some confidence in the sector.

The bounce follows a sharp selloff across Korea, Japan and the US, where investors briefly questioned whether the AI chip rally had run too far, too fast.

The reversal began after one of the sharpest global chip selloffs of the year.

Samsung Electronics reported preliminary second-quarter operating profit of 89.4 trillion won on Tuesday, with sales of about 171 trillion won, confirming a record quarter driven by AI memory demand.

But instead of rallying, Korean chip stocks sold off as investors treated the results as a “sell-the-news” moment.

South Korea’s Kospi fell into technical bear-market territory on Wednesday, down 22.8% from its June 22 peak.

Samsung lost 6.3% and SK Hynix dropped 5.7% in that session, extending a two-day rout tied to fears about stretched AI valuations, higher oil prices and interest-rate risk.

The earlier selling was even more dramatic as the Kospi ended 7.9% lower last week, with SK Hynix down 14.6%, Samsung off 9.1% and Japan’s Kioxia tumbling more than 13.5% as the memory trade unwound.

By Thursday, dip-buying had returned. Kioxia rose 8.3% in Japan, while Samsung and SK Hynix also gained as investors rotated back into memory names ahead of SK Hynix’s US listing.

The reason the rebound has traction is that analysts have not treated the pullback as a break in the AI cycle.

Bank of America’s Vivek Arya reiterated a Buy rating on Micron and kept a $1,550 price target.

Arya argued that global cloud and AI infrastructure spending could reach $1.5 trillion by 2027, with 35%-40% directed toward memory components.

His view is that investors are underestimating how memory is shifting from a deeply cyclical product into a strategic AI resource.

UBS also stayed bullish on memory. The firm raised its DRAM contract-price forecasts, with DDR prices now expected to rise 32% quarter-on-quarter in the third quarter, nearly double its earlier 17% forecast.

AMD has its own bull case as Goldman Sachs analyst James Schneider raised his AMD target to $640 from $450, citing strong AI demand and the rising role of high-performance CPUs in agentic AI workloads.

Intel’s rebound story is more about turnaround as HSBC analyst Frank Lee doubled his Intel target to $200 from $100, saying server CPU growth and the foundry business could deliver more value than investors expect.

HSBC expects design commitments in Intel Foundry to begin in the second half of 2026.

Also read- Intel, AMD stocks outperformed Nvidia in H1: what's next?

The bullish notes do not remove the risks and Intel is the clearest example of the same phenomenon.

HSBC’s $200 target is far above broader Street expectations, and the thesis depends heavily on foundry customers turning early engagement into real design commitments.

There is also a broader valuation issue as Bank of America’s bubble-risk warning for technology and semiconductor stocks earlier this month showed that even bullish analysts are watching how crowded the trade has become.

The next tests arrive quickly. SK Hynix’s Nasdaq ADRs are due to begin trading on July 10, after Reuters reported that the $28 billion US share sale was more than seven times oversubscribed.

That debut will be a real-time measure of investor appetite for AI memory exposure.

While temperatures have been scorching across much of the U.S., AI chip stocks have cooled off, with the sector facing increased selling pressure this summer. The dip appears largely centered on concerns that AI infrastructure spending could slow. However, hyperscalers have largely indicated that their capital expenditures will only increase next year, and Bank of America recently projected that worldwide, cloud and AI data center capex will jump by 40% to 50% year over year to around $1.5 trillion in 2027.

With data center infrastructure spending still booming, this pullback could be a great chance to scoop up these three AI semiconductor stocks. 

1. Nvidia: Still leading the way

Today's Change

(

3.74

%) $

7.37

Current Price

$

204.30

Nvidia (NVDA +3.74%) remains the king of AI infrastructure, and following the pullback, it trades at just 15 times analysts' estimated earnings for its fiscal 2028 (which ends in January 2028). That's a bargain for a company that is still delivering rapid revenue growth, including 85% growth last quarter.

What I really like about Nvidia, though, is how the company has quietly transformed itself into a complete AI infrastructure package. The company's graphics processing units (GPUs) remain its biggest revenue driver, and its ubiquitous CUDA software platform provides a wide moat for its chips in AI model training.

However, the company also has a top-notch networking portfolio; its "acquisition" of Groq gave it a chip designed specifically for inference; and it's diving headfirst into the data center central processing unit (CPU) market, which is set to boom as the use of agentic AI takes off. This lets it offer complete end-to-end systems for specific AI tasks and should help drive continued strong growth.

At its current valuation, Nvidia is a stock to own.

2. AMD: Riding inference and agentic AI trends

Today's Change

(

0.37

%) $

1.91

Current Price

$

518.02

Advanced Micro Devices (AMD +0.37%) stock has been hot this year, but it, too, has pulled back from its highs. The exciting thing about AMD is that it is riding two of the most powerful trends in AI right now.

The first is inference, where its GPUs compete well against Nvidia's offerings, given their chiplet design, which allows them to be packaged with more memory. AMD has formed partnerships with OpenAI and Meta Platforms, and big orders for its newest GPUs should begin shipping soon. It's also been reported that it may have a deal with Anthropic.

On top of that, AMD is a leader in data center CPUs. 

Because CPUs are the right hardware for managing AI agents, the number of CPUs used in AI data centers is expected to skyrocket. Where previously, the ratio of GPUs to CPUs in AI data center servers built for training stood at 8:1, experts foresee that ratio evolving to 1:1 with infrastructure designed to support agentic AI. AMD sees the total addressable market for data center CPUs growing at a 35% annualized rate to $120 billion by 2030.

Between its GPU and CPU opportunities, AMD looks poised for strong growth.

Image source: Getty Images.

3. Broadcom: The custom chip leader

Today's Change

(

5.00

%) $

18.53

Current Price

$

389.31

Broadcom (AVGO +5.00%) is another company on the verge of explosive revenue growth that has been caught in the AI infrastructure sell-off. The pullback in the stock has taken its valuation down to just 19 times analysts' earnings estimates for its fiscal 2027 (which ends in November 2027).

However, the company should see its custom chip revenue surge to well over $100 billion next year. That's more than the nearly $64 billion in total revenue it generated last year and five times the AI revenue it produced. The company's custom chip business is taking off with the success of Alphabet's Tensor Processing Units (TPUs), which it helped the search leader develop. That has led to other hyperscale customers turning toward its ASIC (application-specific integrated circuit) services to help them develop custom AI chips.

Broadcom has also been a leader in data center networking. This is a fast-growing business that can also tie directly into its custom chip business. Given the company's growth prospects, the stock is just too cheap at these levels.

President Donald Trump has been more involved in the stock market than past presidents.

He's made some timely calls, notably telling investors to buy stocks after the market meltdown in April when he announced high tariff rates on most of the country's major trading partners.

The Trump administration has also had the U.S. government take stakes in companies it deems imperative to national security. Some of the government's picks, like Intel, have turned into extraordinary investments.

Recently, Trump has been touting and buying Dell (DELL +3.69%) stock. Should you?

Image source: Joyce N. Bhoghosian.

Why does Trump like Dell? Michael and Susan Dell donated $6 billion to power the new Trump Accounts, which are tax-advantaged accounts that parents can use to start building savings for their children as soon as they are born.

Eligible newborn babies born between the start of 2025 and the end of 2028 can also receive a free $1,000 contribution to the accounts.

"Go out and buy a Dell computer," Trump, who made a similar pitch in May, said on July 6. "We're going to get him that money back one way or the other -- and then I'll ask for another $6 billion. ... We'll start the whole process all over again."

Although the U.S. government doesn't hold a stake in Dell, 2025 financial disclosures show that Trump made 24 trades in Dell last year, with $545,000 in net purchases.

Dell has benefited from the AI trade Trump's bullish calls may help Dell, but the company has already benefited immensely from its involvement in the artificial intelligence trade, with the stock up more than 230% this year.

Similar to other AI plays that have done well, Dell is a pick-and-shovel play. The company builds servers that house graphics processing units (GPUs). Dell's servers help the GPUs run properly by cooling them, managing power distribution, and connecting them to other GPUs and storage within data centers.

So, as GPU clusters scale, Dell sees more demand for its servers. In Dell's first fiscal quarter of 2027, which ended May 1, revenue surged by 88% year over year, while diluted earnings per share surged 282%. More than 37% of Dell's total first-quarter revenue came from AI servers alone.

Today's Change

(

3.69

%) $

15.41

Current Price

$

432.69

After the earnings report, Piper Sandler analyst James Fish raised his price target on Dell to $497, implying about 19% upside from the July 7 closing price of about $417.

"This was not just a one-quarter phenomenon either, as the team is seeing backlog and pipelines outpace sales growth, though admitting that some of this is due to net pull-in of demand given the ongoing supply chain issues across the space and raised pricing," Fish wrote in his research note at the time.

One issue with Dell is that it's not exactly a high-margin story. Even as revenue has surged, the company's gross margin has declined by more than 300 basis points from 21.1% a year ago to 17.8% in its first quarter.

Should you buy the stock? The company's valuation reflects some of the margin issues. Dell trades at about 21 times forward earnings and 1.6 times forward sales, which isn't low per se, but not nearly as high as some other high-flying AI stocks.

Dell also has a large personal computer business, which, while no longer the company's main focus, remains a segment that management hopes to rejuvenate. The company wants to offer products with greater variety in price points and features.

While I am wary of all companies whose stocks have ripped higher on the AI trade right now, Dell by no means trades at an outlandish valuation compared to others. However, if you do buy the stock, I would dollar-cost average to smooth out your cost basis over time, as AI names are likely to experience high volatility.

9.7.2026 12:29, PEP

Americký výrobce nápojů a potravin PepsiCo zveřejnil výsledky hospodaření za druhé čtvrtletí roku fiskálního roku 2026, které skončilo 13. června 2026. Organické tržby vzrostly o 2,4 %, čímž mírně zaostaly za odhadem analytiků, přičemž segment potravin v Severní Americe organicky klesl o 2 %. Tržby a jádrový zisk na akcii odhady mírně překonaly a společnost potvrdila celoroční výhled organického růstu tržeb.

Výsledky společnosti PepsiCo (PEP) za 2Q FY 2026   2Q FY 2026 Konsensus 2Q FY 2026 2Q FY 2025 Tržby (mld. USD) 24,18 23,95 22,73 Provozní zisk (mld. USD) 4,02 4,06 1,79 Jádrový zisk na akcii (Core EPS, USD/akcie) 2,20 2,19 2,12 Výsledky za 2Q FY 2026 Tržby meziročně vzrostly o 6,4 % na 24,18 mld. USD a překonaly odhad 23,95 mld. USD. Organické tržby vzrostly o 2,4 % (odhad: +2,54 %), přičemž loňský výsledek byl +2,1 %.

Tržby PepsiCo ve 2Q FY 2026 dle segmentů
(mld. USD) Segment Tržby Konsensus Meziroční změna Nápoje Severní Amerika (PBNA) 7,24 7,20 +6,5 % Potraviny Severní Amerika (PFNA) 6,37 6,48 –1,7 % Evropa, Blízký východ a Afrika (EMEA) 4,98 4,89 +9,9 % Potraviny Latinská Amerika 2,94 2,86 +15 % Mezinárodní franšíza nápojů (IB Franchise) 1,52 1,46 +11 % Asie a Tichomoří 1,12 1,06 +12 % Z hlediska organického růstu tržeb si mezinárodní segmenty vedly výrazně lépe než Severní Amerika – mezinárodní franšíza nápojů vzrostla o 9 %, EMEA o 6 % a Latinská Amerika o 4 %. Potraviny v Severní Americe organicky klesly o 2 %, nápoje v Severní Americe vzrostly o 1 %.

Provozní zisk dosáhl 4,02 mld. USD, mírně pod odhadem 4,06 mld. USD. Jádrová provozní marže se meziročně mírně snížila o 40 bazických bodů na 16,8 %.

Výhled na FY 2026 Společnost potvrdila celoroční výhled a nadále očekává:

Organický růst tržeb +2 % až +4 % (odhad: +2,76 %) Růst jádrového zisku na akcii v konstantních měnách +4 % až +6 % Firma zároveň očekává, že ve fiskálním roce 2026 navrátí akcionářům přibližně 8,9 mld. USD, z toho dividendy 7,9 mld. USD a zpětné odkupy akcií 1,0 mld. USD. 

Komentář vedení „Výsledky druhého čtvrtletí přinesly silný organický růst objemů i tržeb v segmentech globálních potravin a nápojů. Od začátku roku vzrostl globální organický objem PepsiCo nejvyšším tempem od roku 2022, a to díky síle mezinárodního byznysu a pokračující evoluce portfolia," uvedl předseda představenstva a generální ředitel Ramon Laguarta. „Do budoucna budeme nadále plnit naše strategické priority se zaměřením na akceleraci růstu tržeb – včetně přepozicování vybraných globálních značek, inovací v oblasti funkčních a nových produktů a investic do cenové dostupnosti. Zároveň zvyšujeme produktivitu napříč celou organizací s cílem zlepšit provozní páku," dodal Laguarta.

Akcie PepsiCo Akcie PepsiCo (PEP) v předburzovní fázi obchodování rostou o 1,08 % na 144,03 USD.

Akcie PepsiCo Inc (PEP) před výsledky uzavřely na 142,51 USD Ukazatel   Ukazatel   Kapitalizace (mld. USD) 194,5 P/E 17,3 Vývoj za letošní rok (%) -0,7 Očekávané P/E 16,6 52týdenní minimum (USD) 133,0 Prům. cílová cena (USD) 165,4 52týdenní maximum (USD) 171,5 Dividendový výnos (%) 4,0 Zdroj: PepsiCo, Bloomberg

Michal Šnobl, Fio banka, a.s.

Sandisk (SNDK +6.77%) has been, by far, the best-performing stock in the S&P 500 this year. The flash memory maker has benefited from the ever-growing demand for memory and storage from AI data centers. The deep imbalance between supply and demand has allowed the company to boost its prices to a remarkable degree, and buyers keep snapping up its products.

And memory prices could surge even higher: Morningstar analyst William Kerwin expects to see that they rose by more than 100% overall in Sandisk's just-ended fiscal 2026, and predicts a nearly 100% rise from there in its fiscal 2027.

There's no doubt that's incredibly good for Sandisk's business. But the stock market is always forward-looking. Investors need to ask whether that predicted growth is already priced into the stock and whether the company can exceed expectations.

Image source: Getty Images.

Is Sandisk stock a buy right now? The memory market has a history of being extremely cyclical. When memory is in short supply, prices soar, and producers commit to building new fabrication facilities to meet demand. But as those fabs come online, the market tends to get hit with a glut of supply, and memory prices plunge. In just a few years, companies can go from extremely profitable, like Sandisk is today, to making pennies per share or even losing money.

Sandisk hasn't been trading as a stand-alone company for long -- it was spun off from Western Digital in February 2025 -- so there's not a lot of history to go on. But after that spinoff, Sandisk released some data that gave investors a good look at what a down cycle can look like for the company. It went from a $1 billion net profit in fiscal 2022 to a $2 billion net loss in fiscal 2023. It was still a loss-making operation in fiscal 2024 and fiscal 2025. It wasn't until the current fiscal year that Sandisk began to see demand spike and prices shoot higher, resulting in a strong gross margin and total profits.

When the current cycle collapses, Sandisk could sink back toward unprofitable territory. The company is investing significant amounts in its own operations and its joint venture with Kioxia. It also spends a steady amount -- over $1 billion per year -- on research and development. Those costs are unlikely to change even when revenue starts declining. They didn't in 2023 or 2024.

Today's Change

(

6.77

%) $

109.48

Current Price

$

1,727.18

Despite management's efforts to mitigate downside risk by signing long-term contracts with large buyers of its memory products, it could face significant pressure on profits as the supply-and-demand imbalance evens out. The long-term trend is for Sandisk to charge less per terabyte of memory over time. So, demand for storage will have to significantly outpace price declines over time, given the company's additional overhead and production costs.

Sandisk stock has sold off by more than 25% from its peak amid a broader semiconductor stock decline. Despite the lower price per share, it still looks fairly expensive for a cyclical stock near the peak of its earnings cycle. Despite the potential for memory prices to double again in the coming year, investors need to consider what comes when the supply-and-demand equilibrium swings back in the other direction. Indeed, Wall Street's estimates for Micron's fiscal 2028 earnings are currently below those for fiscal 2027. And 2029 could see a huge revenue collapse. At the current price, the stock looks far too expensive to take that long-term risk.

With all the excitement around Space Exploration Technologies, or SpaceX, still fresh in investors' minds, it's understandable if Tesla (TSLA 2.18%) has somewhat faded from investor attention. However, that shouldn't detract from the fact that there's been news on the company recently, some of it good, some bad, and more to come in the near term.

First, the bad news on Tesla Tesla is behind schedule on its robotaxi rollout. While recognizing that the rollout is not entirely under the company's control, the reality is that investors key in on what management tells them. Unfortunately, Tesla is not a company known for underpromising and overdelivering, especially when it comes to the robotaxi rollout.

Image source: The Motley Fool.

Back on an earnings call in July 2025, CEO Elon Musk said, "I think we'll probably have autonomous ride-hailing in probably half the population of the U.S. by the end of the year." Furthermore, going back to the fourth-quarter earnings presentation in January, the company said the robotaxi "status" for seven cities was "H1 2026." That was later changed to "ramping unsupervised" for Dallas and Houston, and "preparations underway" for Phoenix, Miami, Orlando, Tampa, and Las Vegas.

Having passed the half-year mark, only Miami has been added to the list of cities with unsupervised robotaxis (and only in a limited section of Miami), after Dallas and Houston were added in the first quarter and Austin in the last quarter.

Today's Change

(

-2.18

%) $

-8.80

Current Price

$

394.10

Does it matter? Whichever way you look at it, Tesla is behind management's previous proclamations on timelines. This matters because investors pencil in the company's earnings and cash flows based on these projections, which then need to be pushed back when timelines are not met. As such, it's not surprising that Tesla's stock price is down 6.7% as of this writing in 2026.

Moreover, investors will need to be patient with robotaxi as Musk was clear in the last earnings call in April that "I think it's not going to make sense for us to deploy unsupervised FSD or robotaxi large scale when we know that there are major architectural improvements to the software that can improve safety," and this implies waiting for v15 of its full-self driving (FSD) software, which Musk expects "hopefully by the end of this year, but certainly by early next year."

Clearly, the key question regarding the robotaxi during the upcoming earnings call is the current status of v15 FSD.

Image source: Tesla.

Tesla's second-quarter delivery total of more than 480,000 blew away the Wall Street consensus of about 406,000. While the bears will be quick to remind the bulls that Tesla isn't a car company (a long-held bullish argument), the reality is that it is good news for Tesla.

Not only does it confirm that the company has moved past the Model Y refresh issue that slowed sales last year, but it also shows it's retaining its market position even as rivals are scaling back their EV plans after failing to gain market share.

Moreover, some back-of-the-envelope calculations show that the 74,000 extra units above Wall Street estimates (assuming an average revenue per unit of $43,000) will result in $3.18 billion in "extra revenue." Given that Tesla's operating cash flow margin was about 15.6% in 2025 and assuming the extra deliveries are capital-spending-neutral, this could result in $500 million in "extra" free cash flow.

That will help derisk Tesla's capital spending plans, which include $25 billion in 2026. As such, the good news on deliveries helps derisk the company's plans.

Earnings season is about to begin, and Delta Air Lines (DAL 1.51%) is one of the first big names up. The carrier reports second-quarter results Friday, July 10, before the market opens, among the earliest S&P 500 companies to do so. With the stock up about 35% this year as of this writing, is it worth buying ahead of the report?

Let's look at what Delta told investors last quarter, what it has guided for this one, and how the valuation stacks up.

Image source: Getty Images.

What Delta set up last quarter When Delta reported March-quarter results in April, the headline was demand. Adjusted revenue rose 9.4% year over year to a record $14.2 billion for the period, and adjusted earnings per share came in at $0.64. Free cash flow was a healthy $1.2 billion. The company also kept paying down debt, trimming adjusted net debt to $13.5 billion, below where it stood in 2019.

More important for Friday is what management guided toward for the June quarter. Delta called for revenue up in the low teens year over year, an operating margin of 6% to 8%, and adjusted earnings per share of $1.00 to $1.50. It expects to lead the industry with about $1 billion in profit for the quarter.

CEO Ed Bastian struck a confident tone.

"In the June quarter, we expect to lead the industry with $1 billion of profit," he said in the company's March-quarter release. He added that while a recent fuel spike is pressuring earnings, "this environment ultimately reinforces Delta's leadership."

That last point is the swing factor. Delta's June-quarter guidance already bakes in higher fuel costs. It assumed all-in fuel of about $4.30 per gallon, and management responded by pulling back on capacity growth to protect margins. So the question Friday isn't just how strong demand was. It's whether Delta held its profit line against a costlier fuel backdrop.

It's also worth remembering how Delta makes its money. Beyond main-cabin ticket sales, the airline leans on a lucrative co-branded credit card program and a growing premium-cabin business. Those higher-margin revenue streams are a big reason Delta consistently out-earns the rest of the industry, and they're part of why management can guide to a $1 billion quarter even with fuel working against it.

Today's Change

(

-1.51

%) $

-1.34

Current Price

$

87.08

Does the setup make the stock a buy? Here's where valuation comes in, and it's the most compelling part of the story. At about $92 per share, Delta trades at roughly 13 times trailing earnings. That's well below the broader market's multiple of more than 20. Rival United Airlines is cheaper still, at about 12 times earnings. In other words, the market is pricing airlines like cyclical, low-quality businesses even as Delta generates industry-leading profits and real free cash flow.

That gap is the bull case. If Delta keeps producing $1 billion quarters and paying down debt, a low-teens earnings multiple looks too cheap for the strongest operator in the group. And the company has given itself levers to defend margins, from cutting capacity to recapturing fuel costs, instead of leaning on strong demand alone.

But should you buy specifically to catch Friday's report?

I'd be careful there. No one can know how a stock will react to a single earnings release, and buying just ahead of one is closer to a coin flip than an investment. Delta delivered last quarter's results within its own guidance despite a fuel spike, but a soft read on demand or an ugly fuel number could send shares lower regardless of how cheap they look.

Overall, I think Delta is an attractive stock at about 13 times earnings for investors willing to hold through the sector's cyclical swings. But the decision shouldn't hinge on Friday's report. Only consider the stock if you like the business and its valuation from a long-term perspective, because there's no way to know how the stock will react after the earnings report drops.

Shares of Palantir Technologies (PLTR 1.57%) got pummeled during the first six months of 2026, with shares plunging 34%, according to data provided by S&P Global Market Intelligence. That's a far cry from the 10% gains of the S&P 500.

Artificial intelligence (AI) stocks have been taking a breather over the past year as investors have grown more discriminating, casting a wary eye on stocks with frothy valuations and looking for the "next big thing." However, Palantir's stellar results and its lower stock price have combined to bring its valuation back to Earth, making the price more reasonable than it's been in some time.

Is the worst over? Let's take a look.

Image source: Getty Images.

The numbers paint a compelling picture Since the start of this year, Palantir has delivered two quarterly financial reports, and each has been better than the last.

For the fourth quarter -- which was reported in early February -- Palantir delivered record revenue that surged 70% year over year and 19% quarter over quarter to $1.4 billion. This marked the 10th successive quarter of accelerating growth. This drove adjusted earnings per share (EPS) of $0.25.

Driving the results was demand for the company's Artificial Intelligence Platform (AIP). U.S. government revenue of $507 million climbed 66% to $570 million, while U.S. commercial revenue -- which includes AIP -- soared 137% to $507 million. Perhaps more telling was Palantir's remaining performance obligation (RPO), commonly called backlog, which surged 143% to $4.21 billion. This shows the company is building a solid foundation for the future.

Palantir's first-quarter results, reported in May, were even better. Revenue jumped 85% year over year to $1.63 billion -- marking the company's highest-ever year-over-year growth rate. This fueled adjusted EPS that surged 154% to $0.33.

Today's Change

(

-1.57

%) $

-2.11

Current Price

$

132.26

While U.S. government revenue grew an impressive 84% year over year, U.S. commercial revenue flew even higher, soaring 133% year over year, as demand for AIP continued to lead the way. At the same time, its RPO jumped 134%. Its Rule of 40 score, which illustrates the balance between the company's strong growth and increasing profitability, reached rarified territory of 145% -- when any number above 40% is considered healthy.

Not only is Palantir attracting new customers, but is also expanding its relationships with existing users, as evidenced by its net dollar retention rate of 150%. Put another way, existing customers spent 50% more, on average, in Q1 than in the year-ago quarter.

Investors have been watching closely over the past year, concerned that AI adoption had peaked, but the evidence clearly suggests otherwise. Palantir increased its full-year 2026 financial guidance and is now anticipating 71% revenue growth, up from its earlier forecast of 61% issued earlier this year.

To the untrained eye, the stock appears somewhat pricey, selling for 149 times earnings -- but that doesn't account for Palantir's accelerating high-double-digit growth. Using the more appropriate price/earnings-to-growth (PEG) ratio -- which factors in the company's phenomenal growth rate -- returns a multiple of 0.52, when any number less than 1 signals an undervalued stock.

Taken together, Palantir's stellar track record, accelerating growth, and moderating valuation make the case that the stock is a buy.

Space Exploration Technologies (SPCX 1.02%), or SpaceX as most know the company, recently became the largest IPO in history. But investors may not realize just how little of the company is currently trading on the market. SpaceX sold 555.6 million shares to public investors, which sounds like a lot, but it's not. That's only about 4% of the total company.

Major investors, employees, and insiders own the rest. That includes CEO Elon Musk, who owns approximately 42% of the company through a combination of more than 4.8 billion shares and stock options. However, Musk is bound to an extended lockup provision that prevents him from selling any of his shares until June of next year, or 366 days after the IPO.

Here's a look at how these provisions might affect SpaceX stock between now and then.

Image source: The Motley Fool.

SpaceX structured its lockup window to minimize volatility Musk and his companies have an enormous following, especially among individual investors. SpaceX tried to account for this when it planned out its lockup periods. Lockups prevent insiders and major investors from dumping shares on the market once a company goes public. Typical lockups expire after 180 days, but SpaceX has staggered its lockups to minimize volatility in its share price.

There are multiple lockups, not including the extended lockup Musk is subject to.

Investors can sell up to 20% of their stock shortly following SpaceX's second-quarter earnings report, its first since the IPO. Another 28% unlocks following the company's third-quarter earnings report. Investors might be able to sell more, based on how the stock is trading at the time.

Additionally, shares will steadily unlock in 7% increments, regardless of share price, on days 70, 90, 105, 120, and 135 after the IPO. Any remaining shares, excluding the extended lockup, unlock at the traditional 180 days.

Today's Change

(

-1.02

%) $

-1.53

Current Price

$

147.94

Musk's eventual lockup expiration could weigh on an expensive stock The important point here is that the number of shares available for trading will increase significantly over the next six months. Although it's unlikely that Musk will dump his stake next year, even trimming it to monetize some of his fortune could continue to push lots of new shares into the market a year after the IPO, after a ton of stock has already flooded the market. That could weigh on the share price without sufficient demand to absorb all those additional shares.

It's not the only factor. SpaceX went public amid a ton of hype and excitement, which drove the stock's valuation to pretty lofty heights. The stock still trades at over 100 times its 2025 revenue of $18.6 billion. In other words, there's a ton of room for shares to fall if sentiment turns south. It's a risk worth considering when deciding whether to buy the stock.

GE Aerospace (NYSE:GE) will release its second quarter earnings report before the opening bell on Thursday, July 16.

Analysts expect the Evendale, Ohio-based company to report quarterly earnings of $1.86 per share, up from $1.66 per share in the year-ago period. The consensus estimate for GE Aerospace’s quarterly revenue is $11.82 billion. It reported $10.15 billion last year, according to Benzinga Pro.

On June 25, GE Aerospace declared a 47 cents per share dividend.

Shares of GE Aerospace fell 3% to close at $356.03 on Wednesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Considering buying GE stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

The logo of Xiaomi appears on a new‑generation SU7 electric sedan ahead of a launch event in Beijing, China, March 19, 2026. REUTERS/Maxim Shemetov/File Photo Purchase Licensing Rights, opens new tab

CompaniesBEIJING, July 9 (Reuters) - China's Xiaomi (1810.HK), opens new tab on Thursday unveiled an SUV series named Sky Nomad, accelerating the technology company's push into automobiles as growth slows in ​its mainstay smartphone market.

The extended-range electric vehicle (EREV) series, branded Xiaomi Pengcheng ‌in Chinese, will comprise "smart, versatile, spacious" SUVs, CEO Lei Jun said on his Weibo micro-blog account along with a teaser poster of one of the vehicles.

Make sense of global markets with the Trading Day newsletter. Sign up here.

EREVs are a type ​of plug-in hybrid that sit between conventional petrol-electric hybrids and battery-only ​vehicles, using a combustion engine as a generator to extend battery ⁠driving range.

Xiaomi's announcement represents expansion beyond battery-powered sedans and crossovers into a ​category popularised by models from automakers such as Li Auto (2015.HK), opens new tab.

With its SU7 sedan ​and YU7 crossover, Xiaomi's EV business has become a revenue pillar over the past two years.

The consumer electronics firm expanded into cars in search of new revenue drivers as ​growth slowed worldwide in the mature smartphone and home appliance markets.

However, the ​auto business remains costly for the tech firm due to the heavy investment needed and narrower ‌profit ⁠margins.

Xiaomi pitches its cars as a high-tech Chinese alternative to models from Tesla (TSLA.O), opens new tab, pitting its SU7 and YU7 lines against the U.S. EV maker's Model 3 and Model Y.

As of the end of June, Xiaomi had delivered 258,232 ​YU7 crossovers in China ​since the model's ⁠June 2025 launch, compared with 471,207 Model Y vehicles sold in the country over the same period, showed data ​from auto information and trading platform DCar.

Xiaomi has locked-in ​orders for ⁠existing models but faces a slowing domestic market and has yet to export its vehicles, unlike many domestic peers. The company plans to launch vehicles in Europe ⁠next ​year.

"They (car owners) want their car to be a ​second home. For them, a car is not merely a means of transport but another moving ​space," Lei said.

Reporting by Ju-min Park and Qiaoyi Li; Editing by Christopher Cushing

Our Standards: The Thomson Reuters Trust Principles., opens new tab

After several years of underperforming the market, Iovance Biotherapeutics (IOVA 1.61%) is finally bouncing back. The biotech company's shares have soared 74% this year. However, the stock still looks pretty cheap -- it is trading for just under $5 apiece. And for what it's worth, several Wall Street analysts think it could rise even more. Its average price target (according to Yahoo! Finance) is $8.80. Should investors rush to buy the company's shares?

Image source: The Motley Fool.

A high-risk, high-reward play Iovance Biotherapeutics developed Amtagvi, an approved medicine for treating melanoma. Amtagvi is manufactured from patients' own cancer-fighting cells, which are harvested, grown in a lab, and then reinserted back into the patient. Amtagvi's sales are growing at a good clip. In the first quarter, Iovance Biotherapeutics' revenue (mostly from this product) increased 45% year over year to $71.4 million. Meanwhile, Iovance Biotherapeutics is making progress in regions outside the U.S. It earned approval for Amtagvi in Canada last year, and could see the medicine's sales improve meaningfully as it ramps up commercial efforts in the country.

Further, Iovance Biotherapeutics could obtain approval for Amtagvi in several other countries, including across the European Union. Launching the medicine in these regions would significantly expand its addressable opportunity, likely even more so than the Canadian market. Elsewhere, the company is making clinical progress. Iovance Biotherapeutics is developing Amtagvi for the treatment of endometrial cancer. The company also boasts several other pipeline candidates. Provided the biotech company can earn significant clinical wins over the next few years while also making solid commercial progress with Amtagvi, it could maintain the momentum it has had so far this year.

Today's Change

(

-1.61

%) $

-0.07

Current Price

$

4.28

However, several factors could derail Iovance Biotherapeutics' plans, including the very real risk of clinical or regulatory setbacks every drugmaker faces. It has already encountered several. For instance, Iovance Biotherapeutics announced earlier this year that it was withdrawing its regulatory application for Amtagvi in the United Kingdom due to "procedural reasons," although it said it would resubmit it promptly. Beyond potential regulatory roadblocks, there is a much bigger issue with the Company. The medicines it develops are complex to manufacture and administer.

It takes about a month for Amtagvi to be manufactured after patients' cells have been harvested. And before receiving treatment, they have to undergo chemotherapy. Can Iovance Biotherapeutics eventually turn a profit, given that its therapies are so complex and expensive to administer? It's not clear that it can, and the company's bull case depends on a lot of things going right. Iovance Biotherapeutics may maintain its momentum if it continues to post strong financial results while eventually earning new approvals and label expansions. But the company is trading at a low price for a reason, and it could fall much further if it faces headwinds. So, Iovance Biotherapeutics is fairly risky, and only investors comfortable with volatility should consider initiating a position.

Modular and scalable test facility drives innovation for electric thrust reverser actuation systems

, /PRNewswire/ -- Collins Aerospace, an RTX (NYSE: RTX) business, announced today its Engineering Center of Excellence in Wolverhampton, U.K. is fully operational, advancing next-generation electric thrust reverser actuation systems (elecTRAS™). The CoE is home to a new state-of-the-art, modular and scalable test facility designed to facilitate innovation in aircraft actuation system design, testing and certification.

With a more streamlined solution, elecTRAS supports the elimination of actuation hydraulic interfaces and fluids and facilitates a 15-20% reduction of the nacelle actuation weight at the integrated aircraft system level. Wolverhampton's advanced testing capabilities simulate real-world conditions for aircraft components, actuators, subsystems, and full systems. By integrating early-stage test results into system analysis, potential issues are resolved quickly, reducing delays and enhancing distinctive design scalability for future applications.

"Our Engineering Center of Excellence reflects RTX's commitment to delivering innovative, efficient and cost-effective solutions for the aerospace industry," said Ajay Mahajan, president of Advanced Structures at Collins Aerospace. "This unique modular approach supports the industry's transition to more-electric systems, aligning with original equipment manufacturers' forward-looking goals while improving fuel efficiency, operational performance, and ease of maintenance." The Wolverhampton test capability spans from modules to integrated systems. This allows for scalability and interchangeability, reducing development time and cost while enabling the facility to support multiple programs and system variants.

Co-located elecTRAS systems and nacelle actuation design expertise streamlines development and fosters efficient collaboration. Highly skilled engineers at the facility are driving innovation in electric systems, smart algorithms, and motor control architecture, while continuing to support current fleets. Already in use on the Airbus A350 family, Collins' elecTRAS technology has logged more than 15 million flight hours and 2.2 million flight cycles on more than 700 aircraft as of 2025.

About Collins Aerospace

Collins Aerospace, an RTX business, provides advanced aerospace and defense solutions across avionics, aircraft interiors, aerostructures and engine components, mission systems, and power and control systems. Our global employees are dedicated to delivering innovative technologies to enhance aircraft performance, passenger comfort, operational safety and reliability.

About RTX

With more than 180,000 global employees, we push the limits of technology and science to redefine how we connect and protect our world. With industry-leading capabilities, we advance aviation, engineer integrated defense systems for operational success, and develop next-generation technology solutions and manufacturing to help global customers address their most critical challenges. The company, with 2025 sales of more than $88 billion, is headquartered in Arlington, Virginia.

For questions or to schedule an interview, please contact [email protected].

SOURCE RTX